

CURRICULUM VITAE

Frank C. Hampel, Jr., M.D.

PERSONAL DATA:

Office Address:

Site Mailing Address:

Central Texas Health Research
705-A Landa Street
New Braunfels, Texas 78130

Research Conducted at:

Central Texas Health Research
705 Landa Street, Suites A, D, & F
New Braunfels, TX 78130

12501 Judson Road #202
San Antonio, Texas 78233

Office Phone:

830-629-9036 or 830-609-0900
FAX: 830-609-0006

Texas State Department of
Public Safety Number:

Available on request

DEA Number:

Available on request

Texas State License Number: E 6399

EDUCATION:

Undergraduate Training

1968-1972

B.S. Texas A & M University with honors
College Station, Texas

Post Graduate Training

1972-1976

M.D. The University of Texas Health
Science Center at San Antonio
San Antonio, Texas

1976-1979	Pediatric Internship and Residence Medical Center Hospital San Antonio, Texas
1983-1985	Fellowship in Allergy-Immunology University of Texas Health Science Center at San Antonio San Antonio, Texas
Board Certification	Pediatrics 1981 Allergy/Immunology 1987

PROFESSIONAL EXPERIENCE:

1979-1983	Four years of private pediatric practice in New Braunfels, Texas
1983-1985	Allergy/Immunology fellowship Assistant Professor, Division of Clinical Immunology, Department of Pediatrics
1985-Present	Private Practice of Allergy in New Braunfels and San Antonio, Texas
1983-Present	Clinical Research Central Texas Health Research New Braunfels, Texas
Staff privileges	1) McKenna Memorial Hospital 143 E. Garza New Braunfels, Texas 78130 (830) 606-9111 2) Village Oaks Medical Center 12412 Judson Rd. San Antonio, Texas 78233 (210) 650-4949 3) Northeast Baptist Hospital 8811 Village Drive San Antonio, Texas 78217 (210) 653-2330

PROFESSIONAL ORGANIZATIONS:

Texas Medical Association	1979-Present
Texas Allergy Society	Feb. 1983-Present
Comal County Medical Society	1979-Present
-Secretary	1986
-Vice President	1987

-President	1988
American Academy of Pediatrics	1979-1985
American College of Allergy, Asthma, & Immunology	1984-Present
Joint Council of Allergy & Immunology	1985-Present
San Antonio Allergy Society	1985-Present
American Academy of Allergy, Asthma, & Immunology	1989-Present

AWARDS DURING FELLOWSHIP:

- 1) Vivonex award winner at the 5th International Food Allergy Symposium presented by the American College of Allergists in Atlanta, Georgia, October 1984.
- 2) American Academy of Allergy and Immunology Schering Travel Grant Award-1985.
- 3) American College of Allergy, Parke-Davis Travel Grant Award-1985.

PAPERS AND PRESENTATIONS:

- 1) Presented at the 5th International Food Allergy Symposium presented by the American College of Allergists in Atlanta, Georgia, October 1984, "Immune Responses to Food Antigens in Atopic Eczema".
- 2) Presented at American College of Allergy, Miami, Fla. 1985, "Evaluation of a New Antihistamine (Acrivastine) Given For Two Weeks in Seasonal Allergic Rhinitis".
- 3) Presented at the 42nd Annual Congress of the American College of Allergy in Phoenix January 1986, "The Clinical Spectrum of Persistent Otitis Media with Effusion (OME) in Children". (collaborated)
- 4) Presented to the American College of Allergists 44th Annual Congress in Boston, September 1987, "Long-Term Efficacy of IgE Pentapeptide Nasal Solution in Allergic Rhinitis". (collaborated)
- 5) Presented at the American Academy of Allergy and Immunology in Baltimore, March 1990, "Double-Blind Randomized Multicenter Trial of Hismanal D in Seasonal Allergic Rhinitis".
- 6) Presented at the American Academy of Allergy and Immunology in Baltimore, March 1990, "Fluticasone Propionate Given Once Daily is as Effective as Beclamethasone Dipropionate Given Twice Daily in Relieving Symptoms of Seasonal Allergic Rhinitis". (collaborated)
- 7) Poster at ACAI meeting in San Francisco, November 1990, "Azelastine Nasal Spray: A Two-Week Safety/Efficacy Study in Seasonal Allergic Rhinitis". P. H. Ratner, M.D.;

- S. R. Findlay, M.D.; J. H. VanBavel, M.D.; F. Hampel, Jr., M.D.; and J. J. Freitag, M.D.
- 8) Poster at ACAI meeting in San Francisco, November 1990, "Fluticasone Propionate is an Effective Treatment for Seasonal Allergic Rhinitis in Adolescents". Z. Munk, M.D.; D. Graft, M.D.; A. Green, M.D.; F. Hampel, M.D.; D. Pearlman, M.D.; W. Pleskow, M.D.; D. Stempel, M.D.; A. vanAs, M.D., PhD.
 - 9) Poster at ACAI meeting in San Francisco, November 1990, "An Evaluation of Duact and its Individual Components in Treatment of Seasonal Allergic Rhinitis". M.F. Frosolono, PhD; S. R. Findlay, M.D.; F. Hampel, M.D.; B. Martin, D.O.; B. Paull, M.D.; P. Ratner, M.D.; J. vanBavel, M.D.; P.A. McSorley, M.D.; J. Wegener, PharmD; R. Sanders, PhD; and B. O. Williams, M.D.
 - 10) Article in Annals of Allergy, October 1991, "Pentigetide Nasal solution: a Multicenter Study Evaluating Efficacy and Safety in Patients with Seasonal Allergic Rhinitis". H.C. Mansmann Jr., M.D.; J. Rosen, M.D.; R. Ziering, M.D.; F. Hampel, M.D.; P. Ratner, M.D.; S. Findlay, M.D.; W. Kniker, M.D.; Z. Haddad, M.D.; and A. Daigle, PhD.
 - 11) Poster at ACAI meeting in New York, November 1991, "A Placebo Controlled Double-Blind Randomized Parallel Study Comparing the Safety and Efficacy of Terfenadine 60 mg BID and Terfenadine 120 mg (2 x 60 mg) QD in the Treatment of Patients with Seasonal Allergic Rhinitis". P.H. Ratner MD; F. C. Hampel, MD; J. Van Bavel MD; B. Paull MD; B.E. McNutt MD; W.J. Huster PhD.
 - 12) Poster at ACAI meeting in New York, November 1991, "A Comparison of Prolert-D (Acrivastine + Pseudoephedrine, P-D), Prolert (Acrivastine, P), Seldane (S), Hismanal (H) and Placebo (PL) for Treatment of Seasonal Allergic Rhinitis". M. Frosolono, S. Findlay, J. Van Bavel, P. Ratner, F. Hampel, B. Martin, B. Paull, J. Hallett, P. K. McSorley, R. Sanders, and B. Williams.
 - 13) Article in Immunology & Allergy Practice, December 1991, "Double-Blind, Ten-Week Trial of Pentigetide (Pentyde) Nasal Solution In Patients With Allergic Rhinitis". Frank C. Hampel, Jr., M.D., Robert W. Ziering, M.D., and Mr. Thomas O. Thayer.
 - 14) Paper presented at AAAI meeting in Orlando, Florida, March 1992, "Intranasal Fluticasone Propionate Once Daily is More Effective Than Terfenadine Twice Daily in Relieving Symptoms of Seasonal Allergic Rhinitis". J. van Bavel, M.D., S. R. Findlay, M.D., Austin, TX, F. Hampel, M.D., B. Martin, D.O., P. Ratner, M.D., San Antonio, TX, T. Simonetto, BSN, J. Beam, BSN, E. Field, Ph.D., P. Rogenes, Ph.D., and Ken Kral, M.D., Research Triangle Park, NC.
 - 15) Paper presented at AAAI meeting in Orlando, Florida, March 1992, "Double-Blind Placebo-Controlled Pediatric Study of Astemizole Suspension in Seasonal Allergic Rhinitis". G. Gross, M.D., Dallas, TX, Hampel, M.D., New Braunfels, TX, B. Paull M.D., Bryan, TX, P. Ratner, M.D., San Antonio, TX, and J. van Bavel, M.D., Austin, TX.

- 16) Paper presented at AAAI meeting in Orlando, Florida, March 1992, "Comparison of Prolert-D (Acrivastine 8 mg + Pseudoephedrine HCL 60 mg), Prolert (Acrivastine 8 mg) Pseudoephedrine HCL 60 mg, and Placebo For Treatment of Seasonal Allergic Rhinitis". B. O. Williams, M.S., W. Beaucher, M.D., P. Boggs, M.D., R. J. Dockhorn, M.D., H.M. Druce, M.D., S. R. Findlay, M.D., F. Hampel, Jr., M.D., M. Lawrence, M.D., B. Martin, D.O., D. Tinkelman, M.D., J. van Bavel, M.D., P. McSorley, M.D., R. Sanders, Ph.D., and M.F. Frosolono, Ph.D., Collaborative Group and Research Triangle Park, N.C.
- 17) Manuscript published in the Journal of Allergy and Clinical Immunology, September 1992, "Fluticasone Propionate Given Once Daily is as Effective for Seasonal Allergic Rhinitis as Beclomethasone Dipropionate Given Twice Daily".
- 18) Ann. Allergy., 66:97, 1991. "An Evaluation of DUACT® and Its Individual Components in the Treatment of Seasonal Allergic Rhinitis". Frosolono, M.F., Findlay, S.R., Hampel, F., Jr., Martin, B., Paull, B., Ratner, P., vanBavel, J., McSorley, P.A., Wegener, J., Sanders, R., and Williams, B.O.
- 19) J. Allergy Clin. Immunol., 89:358, 1992. "Comparisons of PROLERT®-D (acrivastine 8 mg + pseudoephedrine HCl 60 mg), PROLERT® (acrivastine 8 mg), Pseudoephedrine HCl 60 mg, and Placebo for Treatment of Seasonal Allergic Rhinitis". Williams, B.O., Beaucher, W., Boggs, P., Dockhorn, R. J., Druce, H., Findlay, S.R., Hampel Jr., F., Lawrence, M., Martin, B., Paull, B., Ransom, J., Ratner, P., Tinkelman, D., vanBavel, J., McSorley, P., Sanders, R., and Frosolono, M.F.
- 20) Eur. J. Allergy Clin. Immunol., 47:177, 1992. "DUACT® and SEMPRESX® Capsules provide a faster onset of relief from allergic rhinitis symptoms than do terfenadine and astemizole". Frosolono, M., Findlay, S., vanBavel, J, Ratner, P., Hampel, F., Martin, B., Paull, B., Hallet, J., McSorley, P., Sanders, R., and Williams, B.
- 21) Poster presented at AAAI meeting in Anaheim, CA, March 1994, "Efficacy and Safety of Fluticasone Propionate Metered Dose Inhaler in Patients with Moderate Asthma". J. Wolfe MD, F. Hampel MD, M. Goldstein MD, L. Mendelson MD, Z. Munk MD, A. Schaberg RN, Kral MS, D. Kellerman, PharmD
- 22) Poster presented at AAAI meeting in Anaheim, CA, March 1994, "Fluticasone Propionate Aqueous Nasal Spray is More Effective Than Astemizole in the Treatment of Seasonal Allergic Rhinitis". R. Lemanske MD, K. Dunn MD, S. Galant, MD, F. Hampel, MD, W. Lumry, MD, F. McCain, MD, M. Noonan MD, D. Pearlman MD, J. Ransom MD, L. Southern MD, P. Rogenes, PhD, E. Field PhD, M. Wisniewski PhD, C. Scott BA.
- 23) Poster presented at AAAI meeting in Anaheim, CA, March 1994, "The Efficacy of Fluticasone Propionate Aqueous Nasal Spray for Treatment of Rhinitis is Dependent on Topical Application". F. Hampel MD, W. Howland MD, B. Martin DO, P. Ratner MD, J van Bavel MD, E. Field PhD, K. Kral MS, C. Scott BA.
- 24) Manuscript published in Pediatric Asthma, Allergy and Immunology, 1994, Vol/Iss/Pg.8/1 (39-25) "Intranasal fluticasone propionate is effective and well-tolerated

- in adolescents with seasonal allergic rhinitis". Z.M.Munk, C.Pearlman, D.Graft, A.Green, F.Hampel, W.Pleskow, D.Stempel, A.VanAs, E.Field, P. Rogenes, K.Kral.
- 25) Poster presented at EAACI meeting in Madrid, Spain, June 1995, "Dose Ranging Study of the Activity and Tolerance of Mometasone Furoate in Seasonal Allergic Rhinitis". E. Bronsky, D. Aaronson, R. Berkowitz, P. Chervinsky, D. Graft, H. Kaiser, B. Moss, R. Nathan, D. Pearlman, P. Ratner, J. Adelglass, D.L. Southern, J. van Bavel, F. Hampel, W. Stricker, J. Fourre, F. Cuss, K. Nolop.
- 26) Manuscript published in The Journal of Allergy and Clinical Immunology, May 1995, "A clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis." Edwin A.Bronsky, MD, Howard Druce, MD, Steven R.Findlay, MD, Frank C.Hampel, MD, Harold Kaiser, MD, Paul Ratner, MD, Martin D.Valentine, MD, and Chester C.Wood, MD Salt Lake City, Utah, St. Louis, Mo., Austin, Texas, New Braunfels, Texas, Minneapolis, Minn., San Antonio, Texas, Baltimore, Md, and Ridgefield, Conn.
- 27) Manuscript published in The Journal of Allergy and Clinical Immunology, May 1995, "Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications." Jay Grossman, MD, Charles Banov, MD, Peter Boggs, MD, Edwin A.Bronsky, MD, Robert J. Dockhorn, MD, Howard Druce, MD, Steven R. Findlay, MD, John W.Georgitis, MD, Frank C.Hampel, MD, Harold Kaiser, MD, Paul Ratner, MD, David G.Tinkelman, MD, Martin D.Valentine, MD, Paul Roszko, RPh, Elena Zegarelli, PhD, and Chester Wood, MD Albany, NY, Charleston, SC, Shreveport, LA, Salt Lake City, Utah, Prairie Village, Kan, St. Louis, MO, Austin, TX, Winston-Salem, NC, New Braunfels, TX, Minneapolis, Minn, SanAntonio, Texas, Atlanta, Ga, Baltimore, Md, and Ridgefield, Conn.
- 28) Paper presented at AAAAI meeting in New Orleans, LA, March 1996, "Comparison of Once-Daily Triamcinolone Acetonide Aqueous Nasal Spray and Twice-Daily Beconase AQ® for the Treatment of Seasonal Allergic Rhinitis Due to Ragweed". C.LaForce M.D., F.Hampel M.D., F.Kiechel M.D., W.Lumry M.D., J.J.Murray M.D., J.A. Furst B.S., B.Simpson B.S., J.A.Smith M.D. Raleigh, NC, New Braunfels, TX, Lincoln, NE, Dallas, TX, Nashville, TN, Collegeville, PA.
- 29) Poster presented at the American Thoracic Society Meeting in New Orleans, LA, May 1996, "Inhaled Fluticasone Propionate Administered Via the Diskus or Diskhaler Multidose Powder Inhalers is Safe and Effective in Adolescent and Adult Subjects with Mild to Moderate Asthma." F.C.Hampel,Jr., J.VanBavel, J.Selner, G.Gross, A.Brown, A.Hamedani, S.Harding, J.Schaumberg, NewBraunfels, Austin, Dallas, TX, Denver, CO, Research Triangle Park, NC.
- 30) Abstract published in The Journal of Allergy and Clinical Immunology, January 1995, "Double Strength Beclomethasone Dipropionate (84 Mcg/Spray) Aqueous Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)." Paper presented during scientific sessions 51st Annual Meeting, AAAI, Feb.24-Mar.1, 1995. B.Prenner,MD, SanDiego,.CA; P.Chervinsky,MD, N.Dartmouth, MA; F.C.Hampel,MD, New

Braunfels, TX; W. C. Howland, MD, Austin, TX; M. Lawrence, MD, Taunton, MA; F.O.Meltzer,MD, SanDiego,CA; Z.M.Munk,MD, Houston, TX; P.H.Ratner,MD, San Antonio, TX; J.Seltzer,MD, San Diego, CA; G.A.Settipane,MD, Providence, RI; R.L.Lorber,MD and J.E.Harrison,MD, Kenilworth, NJ.

- 31) Abstract published in The Journal of Allergy and Clinical Immunology, January 1995, "Prophylactic Use of Triamcinolone Acetonide Nasal Inhaler in Patients with Seasonal Ragweed Induced Allergic Rhinitis," Paper presented during scientific sessions 51st Annual Meeting. AAAI, Feb.24-Mar.1, 1995. Z.Munk,MD; G.Gross,MD; F.Hampel,Jr.,MD; P.Ratner,MD; J.Lim,MD; and C.McNally,MD. Houston, Dallas, New Braunfels, and San Antonio, TX and Collegeville, PA.
- 32) Manuscript published in Clinical Therapeutics, July-August 1996, "Effectiveness of Fluticasone Propionate in Patients with Moderate Asthma: A Dose-Ranging Study," James D.Wolfe, MD, John C.Selner, MD, Louis M.Mendelson, MD, Frank Hampel,Jr., MD, and Amy Schaberg, RN. Allergy and Asthma Associates of Santa Clara Valley, San Jose, CA; Allergy Respiratory Institute, Denver, CO; Pediatric and Adult Allergy, W.Hartford, CN; Asthma, Allergy, and Immunology, New Braunfels, TX; and Glaxo Wellcome Inc., Research Triangle Park, NC.
- 33) Poster presented at ACAAI Meeting in Boston, Massachusetts, November 8-13, 1996, "A Comparison of Brompheniramine (BR) and Terfenadine (TF) for Symptoms of Seasonal and Perennial Allergic Rhinitis". HM Druce MD, SA Furey, PhD, MD, P Ratner MD, FC Hampel Jr. MD, JH van Bavel MD, EA Lockhart MD, BJ Stern, WR Thoden Madison, NJ, San Antonio, New Braunfels, and Austin, Texas.
- 34) Abstract published in The Journal of Allergy and Clinical Immunology, January 1997, "Superior Improvement in Disease-Specific Quality of Life for SAR Patients Receiving Intranasal Fluticasone vs Loratadine Tablets." B.Goodwin, B.Bowers, F.Hampel, C.Cook, R.Westlund, F.Cox, Glaxo Wellcome Inc, RTP, NC; Central Texas Health Research, New Braunfels, TX.
- 35) Abstract published in The Journal of Allergy and clinical Immunology, January 1997, "The Efficacy and Safety of Fluticasone Propionate (FP) Aqueous Nasal Spray and Loratadine (LOR), Alone and in Combination, in the Treatment of Seasonal Allergic Rhinitis (SAR)." P.H.Ratner,MD, J.H.vanBavel,MD, B.G.Martin,DO, F.C.Hampel,Jr.,MD, W.C.Howland,III,MD,PhD, P.R.Rogenes,PhD, R.Westlund,MS, C.K.Cook,MS. San Antonio,TX; Austin,TX; San Antonio,TX; New Braunfels,TX; RTP,NC.
- 36) Abstract published in The Journal of Allergy and Clinical Immunology, January 1997, "Efficacy and Safety of Levocabastine Nasal Spray for Seasonal Allergic Rhinitis. F.Hampel, B.Martin, J.Dolen, S.Algeo, K.Karcher, D.Holton, Central Texas Health Research, New Braunfels, TX, Southwest Asthma and Allergy Center, San Antonio, TX, and Janssen Research Foundation, Titusville, NJ.
- 37) Manuscript Published in Clinical Therapeutics, Vol. 18, Number 6,Nov-Dec 1996, "The Efficacy of Fluticasone Propionate Aqueous Nasal Spray for Allergic Rhinitis and Its Relationship to Topical Effects." W.C. Howland III, MD, F.C. Hampel, Jr., MD,

B.G. Martin, DO, P.H. Ratner, MD, J.H. vanBavel, MD, and E.A. Field, PhD.
HealthQuest Therapy and Research Institute, Inc. Austin, Central Texas Health
Research, New Braunfels, Southwest Allergy and Asthma Research, San Antonio,
Sylvana Research, San Antonio, Allergy Associates of Austin Diagnostic Clinic,
Austin, and Glaxo Wellcome Inc., Research Triangle Park, NC.

- 38) Abstract published in The Journal of Allergy and Clinical Immunology, July 1997, "Dose Ranging Study of Mometasone Furoate (Nasonex) in Seasonal Allergic Rhinitis". Edwin A Bronsky, MD; Donald W Aaronson, MD; Robert B Berkowitz, MD; Paul Chervinsky, MD; David Graft, MD; Harold B Kaiser, MD; Burton Moss, MD; Robert A Nathan, MD; David S Pearlman, MD; Paul H Ratner, MD; Jeffrey M Adelglass, MD; D Loren Southern, MD; Julius van Bavel, MD; Frank Hampel, MD; William E Stricker, MD; Jon A Fourné; Francis M Cuss, MD; and Keith B Nolop, MD.
- 39) Manuscript Published in American Journal of Rhinology, Vol. 13, Number 1, January-February 1998, "Efficacy and Safety of Levocabastine Nasal Spray for Seasonal Allergic Rhinitis, Frank C. Hampel, Jr., MD, Bruce G. Martin, M.D., Suzanne Travers, M.D., Keith Karcher, and Denise Holton. Central Texas Health Research, New Braunfels, TX, Southwest Asthma and Allergy Center, San Antonio, TX, and Janssen Research Foundation, Titusville, NJ.
- 40) Poster presented at AAAAI meeting at Washington D.C. in 1998 and abstract published in The Journal of Allergy and Clinical Immunology, January 1998, "HFA-Beclomethasone Dipropionate (HFA-BDP) is Effective at Improving Asthma at Doses as Low as 50mcg Twice Daily". F. Hampel, J. VandenBurgt, P. Stampone, Central Texas Health Research, New Braunfels, TX, 3M Pharmaceuticals, St. Paul, MN.
- 41) Poster presented at ACAAI meeting in Chicago, IL, November 1999, "Once-Daily Budesonide (Pulmicort Turbuhaler®) Improves Quality of Life in Adult Asthmatics Previously Treated with Inhaled Steroids". M. Goldstein MD, C. Banov MD, B. Liljas PhD, K. Walton-Bowen MSc Cstat, F. Hampel MD.
- 42) Abstract published in The Journal of Allergy and Clinical Immunology, July 1999, "A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis". E. Meltzer, MD; W. Berger, MD; R. Berkowitz, MD; E. Bronsky, MD; D. Dvorin, MD; A. Finn, MD; S. Galant, MD; J. Grossman, MD; F. Hampel, MD; P. Ratner, MD; M. Ruff, MD; E. Schenkel, MD; A Segal, MD; N. Segall, MD; G. Stewart, MD; I. Tripathy, MD; D. Skoner, MD; R. Anolik, MD; R. Dockhom, MD; J. vanBavel, MD; B. Mesarina-Wicki, MD; and K. Nolop, MD.
- 43) Abstract at AAAAI meeting at San Diego, CA in March 2000, "Ebastine 20mg Once Daily (OD) Given With Food (EWF) or Without Food (EWO) IS Equally Efficacious in the Treatment of Seasonal Allergic Rhinitis (SAR)". F Hampel, Jr, the Ebastine Study Group, JC Lim, M Gillen, S Rohatagi, GC Georges, Central Texas Health Research, New Braunfels, TX; Rhone-Poulenc Rorer Pharmaceuticals, Inc, Collegeville, PA.
- 44) Manuscript Published in Journal of Asthma, Vol. 37, Number 5, 2000, "Effectiveness of Low Doses (50 and 100 µg b.i.d.) of Beclomethasone Dipropionate Delivered as a CFC-Free Extrafine Aerosol in Adults with Mild to Moderate Asthma", Frank Hampel,

M.D., Edward Linsberg, M.D., Jean-Claude Guérin, and the Study Group. Central Texas Health Research, New Braunfels, TX, Asthma and Allergy Center of Chicago SC, River Forest, IL, Hôpital de la Criox-Rousse, Lyon, France.

- 45) Poster presented at AAAAI meeting at Seattle, WA in November 2000, “Fluticasone Propionate Aqueous Nasal Spray for the Treatment of Sinus Pain and Pressure Associated with Nasal Congestion in Patients with Allergic Rhinitis”. Martin, BG; Hampel Jr, FC; van Bavel, JH; Prillman, BA; Reed, KD; Cook, CK; Crim, C.
- 46) Poster presented at AAAAI meeting at New Orleans, LA. in March 2001 and abstract published in The Journal of Allergy and Clinical Immunology, February 2001, “Montelukast in the Treatment of Spring Allergic Rhinitis in a Large, Double-Blind, Randomized, Placebo-controlled Study”. K. Malmstrom, F. Hampel, G. Phillip, M.P. Malice, T. Reiss, Merck Spring Rhinitis Investigator Group. Merck & Co, Inc, Rahway, NJ, Central Texas Health Research, New Braunfels, TX.
- 47) Poster presented at AAAAI meeting in New York, NY in March 2002 and abstract published in The Journal of Allergy and Clinical Immunology, January 2002, “Tecastemazole Produces Rapid and Sustained Symptom Reduction in Seasonal Allergic Rhinitis”. P. Ratner, MD; F. Hampel, MD; and R. Baumgartner, Sylvania Research, San Antonio, TX, Central Texas Health Research, New Braunfels, TX, Sepracor Incorporated, Marlborough, MA.
- 48) Poster presented at AAAAI meeting in New York, NY in March 2002 and abstract published in The Journal of Allergy and Clinical Immunology, January 2002, “Fluticasone propionate aqueous nasal spray provides greater improvement than placebo in the symptoms of rhinitis when used as-needed (PRN)”. F. Hampel, MD; BT Boch; ST Goode-Sellers; LA Witham; CK Cook; and EE Pilpot; Central Texas Health Research, New Braunfels, TX, Bock Clinical research, Harleysville, PA, GlaxoSmithKline, RTP, NC.
- 49) Poster presented at AAAAI meeting in New York, NY in March 2002 and abstract published in The Journal of Allergy and Clinical Immunology, January 2002, “Reduction of eosinophil counts by montelukast in double-blind, randomized, placebo-controlled studies of seasonal allergic rhinitis”. S. Ritter; G.Phillip; F. Hampel, MD; k. Malmstrom; MP Malice; T. Reiss; and Montelukast Seasonal Allergic Rhinitis Group; Merck & Co, Inc, Rahway, NJ and Central Texas Health Research, New Braunfels, TX.
- 50) Poster presented at EAACI meeting in Naples, Italy on June 3, 2002, “Ebastine is efficacious in the control of the nasal congestion associated to allergic rhinitis”. P. Ratner, F. Hampel, Jr., J. Gispert; Sylvania Research, San Antonio, TX, Central Texas Health Research, New Braunfels, TX, and Almirall Prodesfarma, Barcelona, Spain.
- 51) Poster presented at EAACI meeting in Naples, Italy on June 3, 2002, “Ebastine 10 and 20 mg are able to control all symptoms associated to allergic rhinitis. An efficacy placebo controlled comparative clinical trial”. F. Hampel, Jr., P. Ratner, J. Gispert; Central Texas Health Research, New Braunfels, TX, Sylvania Research, San Antonio, TX, and Almirall Prodesfarma, Barcelona, Spain.

- 52) Manuscript Published in Clinical and experimental Allergy, **32**, 2002, “Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring”, G. Phillip, K. Malmstrom, F.C. Hampel, Jr, S.F. Weinstein, C.F. LaForce , P.H. Ratner, M.P. Malice, and T.F. Reiss for the Montelukast Spring Rhinitis Study Group.
- 53) Poster presented at ACAAI meeting in San Antonio, Texas in November 2002, “A Double-Blind, Randomized Comparison of Fexofenadine 180 mg versus Cetirizine 10 mg: Effect on Drowsiness”. FC Hampel, S Korpi, K Reneau, S Meeves, Y Liao, GC Georges: New Braunfels, TX, Bridgewater, NJ.
- 54) Poster presented at ACAAI meeting in San Antonio, Texas in November 2002, “Once Daily Administration of Mometasone Furoate by Dry Powder Inhaler Improves Pulmonary Function and Asthma Symptoms in Patients with Mild to Moderate Persistent Asthma”. GW Bensch, J Corren, S Shah, FC Hampel, H Sacks; Stockton, CA, Los Angeles, CA, Collegeville, PA, New Braunfels, TX, Kenilworth, NJ.
- 55) Abstract presented at the European Respiratory Society 2003 Annual Congress, 2003, “Once-Daily, Evening Administration of Mometasone Furoate Dry Powder Inhaler Improves Pulmonary Function in Patients with Mild to Moderate Persistent Asthma”. G Bensch, F Hampel, H Sacks; Stockton, CA, New Braunfels, TX, Kenilworth, NJ.
- 56) Abstract presented at AAAAI meeting in Denver , CO in March 2003, “Intranasal Fluricasone Propionate Provided Greater Relief Compared to Oral Montelukast for Nasal Congestion and Other Daytime and Evening Nasal Symptoms of Seasonal Allergic Rhinitis.” BG Martin, CP Andrews, JH vanBavel, FC Hampel, EE Philpot, CA Baidoo, KA Rickard; San Antonio, TX, Austin, TX, New Braunfels, TX, Research Triangle Park, NC, Mississauga, ON, Canada.
- 57) Poster presented at ACAAI meeting in New Orleans, LA in November 2003, “Onset of Action of Montelukast in the Treatment of Seasonal Allergic Rhinitis”. G Philip, MP Malice, AS Swern, SF Weinstein, FC Hampel, TF Reiss; Rahway, NJ, Huntington Beach, CA, New Braunfels, TX.
- 58) Oral presentation by Dr. Eli Meltzer in New Orleans, LA in November 2003, “Olopatadine HCl Nasal Spray is Effective and Safe for the Treatment of Seasonal Allergic Rhinitis”. EO Meltzer, F Hampel, P Ratner, D Bernstein, S Gawchik, L Larsen, W Berger, A Finn, GM Wall, M Brubaker, C Dimas, S Potts, L Silver; San Diego, CA, New Braunfels, TX, San Antonio, TX, Cincinnati, OH, Upland, PA, Salt Lake City, UT, Mission Viego, CA, Charleston, SC, Fort Worth, TX.
- 59) Manuscript Published in Annals Of Allergy, Asthma & Immunology, Vol. 94, Number 4, October 2003, “Fexofenadine HCl, 180mg, Exhibits Equivalent Efficacy to Cetirizine, 10 mg, With Less Drowsiness in Patients With Moderate-To-Severe Seasonal Allergic Rhinitis.” F Hampel, P Ratner, L Mansfield, S Meeves, Y Liao, G Georges.

- 60) Manuscript Published in Annals Of Allergy, Asthma & Immunology, Vol. 21, Number 1, January/February 2004, "Once-Daily Budesonide Inhalation Powder (Pulmicort Turbuhaler®) Improves Health-Related Quality of Life in Adults Previously Receiving Inhaled Corticosteroids." F Hampel, M Sugar, B Parasuraman, T Uryniak, B Liljas..
- 61) Abstract presented at the AAAAI meeting in San Francisco, California on March 20, 2004, "Improved Quality of Life (QoL) Among Seasonal Allergic Rhinitis (SAR) Patients Treated With Olopatadine HCl Nasal Spray, 0.4% and Olopatadine HCL Nasal Spray, 0.6% Compared to Vehicle". FC Hampel, PH Ratner, NJ Amar, JH van Bavel, D Moha, K Venkataraman, GM Wall, M Brubaker, M Drake, K Krenshaw; New Braunfels, TX, San Antonio, TX, Waco, TX, Austin, TX, Kerrville, TX, Alcon Research Ltd., Fort Worth, TX.
- 62) Abstract presented at the AAAAI meeting in San Francisco, California on March 20, 2004, "Dose Dependent Effectiveness of Ciclesonide Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)". PH Ratner, JH van Bavel, F Hampel, MA Wingertzahn, PF Darken, T Shah, S Hellberdt, S Brookman; San Antonio, TX, Austin, TX, New Braunfels, TX, ALTANA Pharma, Florham, NJ, ALTANA Pharma, Konstanz, Germany, Clinical Research and Regulatory Affairs, Teijin America, Inc., Princeton, NJ.
- 63) Abstract presented at the AAAAI meeting in San Francisco, California on March 22, 2004, "Olopatadine HCl Nasal Spray Is Effective and Safe for the Treatment of Seasonal (Mountain Cedar) Allergic Rhinitis". PH Ratner, FC Hampel, NJ Amar, JH vanBavel, D Mohar, GM Wall, M Brubaker, M Drake, S Potts; San Antonio, TX, New Braunfels, TX, Waco, TX, Austin, TX, Kerrville, TX, Alcon Research, Ltd., Fort Worth, TX.
- 64) Manuscript published in Clinical & Experimental Allergy, Vol. 34, Issue 6, June 2004, "Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis." DI Bernstein, AL Levy, FC Hampel, CA Baidoo, CK Cook, EE Philpot, KA Rickard.
- 65) Abstract presented at the AAAAI meeting in Boston, Massachusetts on November 13, 2004, "Safety and Tolerability of Fexofenadine in Children Aged 2-5 Years With Allergic Rhinitis". H Milgrom, R Lanier, FC Hampel, B Kittner; Denver, CO, Fort Worth, TX, New Braunfels, TX, Bridgewater, NJ.
- 66) Abstract presented at the AAAAI meeting in Boston, Massachusetts on November 13, 2004, "Safety and Tolerability of Fexofenadine in Children Aged 6 Months to 2 Years With Allergic Rhinitis". FC Hampel, JH van Bavel, B Kittner; New Braunfels, TX, Austin, TX, Bridgewater, NJ.
- 67) Poster presented at ACAAI meeting in Anaheim, California on November 4-9, 2005, "Ciclesonide Nasal Spray Exhibits Dose-Dependent Effectiveness in the Treatment of Seasonal Allergic Rhinitis". P Ratner, M Wingertzahn, J van Bavel, F Hampel, P Darken, T Shah, S Hellbardt, S Brookman; San Antonio, TX, Florham Park, NJ, Austin, TX, New Braunfels, TX, Konstanz, Germany, Princeton, NJ.

- 68) Poster presented at ACAAI meeting in Anaheim, California on November 4-9, 2005, "Generic Fluticasone Propionate Aqueous Nasal Spray (FPANS) for Seasonal Allergic Rhinitis is Equivalent to Flonase[®]". F Hampel, W Howland, B Martin, D Mohar, P Ratner, J van Bavel, V Brandi, E Stahl; New Braunfels, TX, Austin, TX, San Antonio, TX, Kerrville, TX, Miami, FL.
- 69) Poster presented at ACAAI meeting in Anaheim, California on November 4-9, 2005, "Effectiveness of Azelastine (Astelin[®]) Nasal Spray Compared to Ceterizine (Zyrtec[®]) Tablets in Patients with Seasonal Allergic Rhinitis". F Hampel, WE Berger, H Sacks; New Braunfels, TX, Mission Viejo, CA, Somerset, NJ.
- 70) Poster presented at ACAAI meeting in Anaheim, California on November 4-9, 2005, "Improvements in Quality of Life, Work, and Activity with Olopatadine Nasal Spray Treatment of Seasonal Allergic Rhinitis: Results of Two Randomized Controlled Trials". E Meltzer, F Hampel, C Fairchild, M Brubaker, G Wall; San Diego, CA, New Braunfels, TX, Fort Worth, TX.
- 71) Poster presented at Psoriasis: Gene to Clinic meeting in London on December 1-3, 2005, "A Phase 2 Study of STA-5326, an Oral IL-12 and IL-23 Inhibitor, in Patients with Moderate to Severe Chronic Plaque Psoriasis (CPP)". K Gordon, E Tschen, N Korman, J Cather, M Gold, F Hampel, S Miller, S Ertel, M Sherman, the 5326-04 Study Group; Skokie, IL, Albuquerque, NM, Cleveland, OH, Dallas, TX, Nashville, TN, New Braunfels, TX, San Antonio, TX, Lexington, MA.
- 72) Manuscript Published in Annals Of Allergy, Asthma & Immunology, Vol. 95, Number 5, November 2005, "Safety and Efficacy of Olopatidine Hydrochloride Nasal Spray for the Treatment of Seasonal Allergic Rhinitis to Mountain Cedar" P Ratner, F Hampel, N Amar, J van Bavel, D Mohar, B Marple, P Roland, G Wall, M Brubaker, M Drake, D Turner, L Silver.
- 73) Poster presented at the AAAI meeting in Miami on March 3-7, 2006, "Efficacy and Safety of Ciclesonide Nasal Spray in the Treatment of Seasonal Allergic Rhinitis". PH Ratner, MA Wingertzahn, JH van Bavel, F Hampel, PF Darken, N Hall, T Shah; San Antonio, TX, Florham Park, NJ, Austin, TX, New Braunfels, TX.
- 74) Manuscript Published in Annals Of Allergy, Asthma & Immunology, Vol. 96, June 2006, "Comparison of Fluticasone Propionate Aqueous Nasal Spray and Oral Montelukast for the Treatment of Seasonal Allergic Rhinitis Symptoms" B Martin, C Andrews, J vanBavel, F Hampel, K Klein, B Prillamin, M Faris, E Philpot.
- 75) Manuscript Published in Allergy & Asthma Proceedings, Vol. 27, Number 3, May-June 2006, "Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared to vehicle placebo" FC Hampel, P Ratner, N Amar, J van Bavel, D Mohar, C Fairchild, G Wall, M Brubaker, M Drake, K Crenshaw.
- 76) Poster presented at ACAAI meeting in Philadelphia, Pennsylvania on November 10-13, 2006, "Long-term Safety of Ciclesonide in Adult and Adolescent Patients With Perennial Allergic Rhinitis". P Chervinsky, S Kunjibettu, FC Hampel, DL Miller, B

- Prenner, G Raphael, N Hall, MA Wingertzan, T Shah; North Dartmouth, MA, Florham, NJ, New Braunfels, TX, Pittsburgh, PA, San Diego, Ca, Bethesda, MD.
- 77) Poster presented at ACAAI meeting in Philadelphia, Pennsylvania on November 10-13, 2006, "Effects of Ciclesonide Nasal Spray on Seasonal and Perennial Allergic Rhinitis Symptoms". PH Ratner, EO Meltzer, JH vanBavel, FC Hampel, W Berger, C LaForce, MA Wingertzahn, PF Darken, S Kunjibettu, N Hall, T Shah; San Antonio, TX, San Diego, TX, Austin, TX, New Braunfels, TX, Mission Viejo, CA, Raleigh, NC, Florham Park, NJ.
- 78) Abstract published in The Journal of Allergy and Clinical Immunology, Vol. 118, No. 5, November 2006, "Efficacy and Safety of Ciclesonide Nasal Spray in the Treatment of Seasonal Allergic Rhinitis". PH Ratner, MA Wingertzahn, JH van Bavel, F Hampel, PF Darken, N Hall, T Shah; San Antonio, TX, Florham Park, NJ, Austin, TX, New Braunfels, TX.
- 79) Manuscript published in Annals of Allergy, Asthma & Immunology, 2006;97:657-663, "Efficacy and Safety of Ciclesonide Nasal Spray in the Treatment of Seasonal Allergic Rhinitis". PH Ratner, MA Wingertzahn, JH van Bavel, F Hampel, PF Darken, S Hellbardt, S Brookman, T Shah; San Antonio, TX, Florham Park, NJ, Austin, TX, New Braunfels, TX.
- 80) Poster presented at ACAAI meeting in San Diego, California on February 23-27, 2007, "Once-daily Fluticasone Furoate Nasal Spray (FF) Provides 24-hour Symptom Relief In Subjects With Seasonal Allergic Rhinitis (SAR) Caused By Mountain Cedar Pollen". FC Hampel, R Jacobs, B Martin, T Toler, A Ellsworth, E Philpot; New Braunfels, TX, San Antonio, TX, Research Triangle Park, NJ.
- 81) Manuscript Published in Allergy & Asthma Proceedings, Vol. 28, Number 2, March-April 2007, "Optimal Dose Selection of Fluticasone Furoate Nasal Spray For The Treatment of Seasonal Allergic Rhinitis in Adults and Adolescents" B Martin, P Ratner, FC Hampel, C Andrews, T Toler, W Wu, M Faris, E Philpot.
- 82) Abstract presented at ACAAI meeting in Dallas, Texas on November 9-14, 2007, "Epinastine HCl Nasal Spray is Effective and Well Tolerated for the Treatment of seasonal Allergic Rhinitis". PH Ratner, NJ Amar, FC Hampel, JH van Bavel, MC Windmann, D Kellerman, W Tian, A Schaberg; San Antonio, TX, Waco, TX, New Braunfels, TX, Austin, TX, Durham, NC.
- 83) Poster presented at ACAAI meeting in Dallas, Texas on November 9-14, 2007, "Once-Daily Mometasone Furoate Dry Powder Inhaler Effectively Controls Asthma in Patients with Moderate Asthma Previously Using Other Inhaled Corticosteroids". J Corren, F Hampel, R Yao; Los Angeles, CA, New Braunfels, TX, Kenilworth, NJ.
- 84) Poster presented at AAAAI meeting in Philadelphia, Pennsylvania on March 14-18, 2008, "Once-Daily is Equivalent to Twice-Daily Treatment with Mometasone Furoate Dry Powder Inhalation in Patients with Persistent Asthma". R Lockey, F Hampel; Tampa, FL, New Braunfels, TX.

- 85) Poster presented at AAAAI meeting in Philadelphia, Pennsylvania on March 14-18, 2008, "Early Bronchodilatory Effects of Budesonide/Formoterol Pressurized Metered-Dose Inhaler (pMDI) Compared With Fluticasone Propionate/Salmeterol Dry Powder Inhaler (DPI) and Albuterol pMDI in Adults with Asthma". F Hampel, P Martin, W Mezzanotte; New Braunfels, TX, Wilmington, DE .
- 86) Manuscript Published in Annals of Allergy, Asthma & Immunology, Volume 100, Number 1, January 2008, "Combination Therapy with Azelastine Hydrochloride Nasal Spray and Fluticasone Propionate Nasal Spray in the Treatment of Patients with Seasonal Allergic Rhinitis." P Ratner, FC Hampel, J Van Bavel, NJ Amar, P Daftary, W Wheeler, H Sacks.
- 87) Poster presented at AAAAI meeting in Washington, DC on March 15, 2009, "Efficacy and Safety of Azelastine Hydrochloride and Fluticasone Propionate Combined in a Single Nasal Spray Delivery Device in Patients with Seasonal Allergic Rhinitis". F Hampel, P Ratner, J Diaz, H Sacks; New Braunfels, TX, San Antonio, TX, Somerset, NJ.
- 88) Abstract published in The Journal of Allergy and Clinical Immunology, Vol. 123, No. 2, February 2009, "Efficacy and Safety of Azelastine Hydrochloride and Fluticasone Propionate Combined in a Single Nasal Spray Delivery Device in Patients with Seasonal Allergic Rhinitis". F Hampel, P Ratner, J Diaz, H Sacks; New Braunfels, TX, San Antonio, TX, Somerset, NJ.

CLINICAL RESEARCH

Studies performed by Central Texas Health Research

ABBOTT LABORATORIES

- 1) A Double-Blind 6-Month Study of the Effects of a New Oral Medication for the Treatment of Moderate Asthma. 24 patients enrolled. 1992-1993.
- 2) Safety and Efficacy Study with a New Oral Asthma Medication for Moderate Asthmatics. 1994.
- 3) Long-Term Surveillance Study of a New Oral Medication for Patients with Asthma. 5 patients enrolled. November 1994.
- 4) A Double-Blind Study to Evaluate the Safety and Efficacy of a New Medication in the Treatment of Mild-Moderate Asthma. 13 patients enrolled. 1996-1997.
- 5) Long-Term Safety Study of a Controlled-Release Once-A-Day Oral Medication Plus Usual Care vs Placebo Plus Usual Care in Patients with Asthma. 27 patients enrolled. 1997.
- 6) A Randomized, Double-blind, Placebo- and Active-Controlled, Parallel Group, 6-Week Study to Evaluate the Effect Multiple Doses of Long-Acting Beta Agonist with a steroid 250/10 µg HFA pMDI twice daily, Long-Acting Beta Agonist with a steroid 100/1µg HFA

pMDI twice daily, Oral Steroid and Placebo on the Hypothalamic-Pituitary-Adrenal Axis in Adult Subjects with Mild to Moderate Asthma. 18 Patients Enrolled. 2008.

ALCON

- 1) A Placebo Controlled, Efficacy and Safety Study of a Nasal Spray for the Treatment of Seasonal Allergic Rhinitis. 45 patients enrolled. 2002.
- 2) A Placebo Controlled, Efficacy and Safety Study of a Nasal Spray for the Treatment of Seasonal Allergic Rhinitis. 165 patients enrolled. 2002-2003.
- 3) A Long Term Safety Study of a Nasal Spray for the Treatment of Perennial Allergic Rhinitis. 25 patients enrolled. 2003-2004.
- 4) Safety and Efficacy of an antihistamine Nasal Spray in Pediatric Patients. 9 patients enrolled. 2005.
- 5) Safety and Efficacy Study of Investigational Antihistamine Nasal Spray versus Investigational Antihistamine Nasal Spray Vehicle versus Marketed Antihistamine Nasal Spray in Treatment of Seasonal Allergic Rhinitis. 46 patients enrolled. 2005.
- 6) Safety Study of Olopatadine Nasal Spray. 15 patients enrolled. 2007.
- 7) Safety and Efficacy of an Intranasal Antihistamine in 6-11 Year Old Patients. 6 patients enrolled. 2007-2008.
- 8) Safety and Efficacy Evaluation of Topical Moxifloxacin/dexamethasone Otic Solution in the Treatment of Acute Otitis Externa. 6 Patients Enrolled. 2008
- 9) Safety and Pharmacokinetics of a Nasal Antihistamine in Pediatric Patients 2 to < 6 Years of Age Who Have a History of Allergic Rhinitis. 23 Patients Enrolled. 2008.
- 10) Safety of a Nasal Antihistamine Nasal Spray in Patients with Perennial Allergic Rhinitis. Still Enrolling. 2008-2009.

ALMIRALL

- 1) A Multi-center, Double-blind, Placebo-controlled, Randomized Comparative Study to Compare the Efficacy and Safety of two antihistamines and placebo All Given Once Daily for Four Weeks in the Treatment of Seasonal Allergic Rhinitis. 42 patients enrolled. 2001.

ALLERGENICS

- 1) A Phase IIB Parallel Group, Placebo Controlled Study of Two Different Maintenance Doses of Orally Administered Microencapsulated Ragweed Pollen. 16 patients enrolled. 2002.

ALLUX

- 1) Simulated Therapy Versus Simulated Placebo in Rhinophototherapy of Seasonal Allergic Rhinitis. 14 patients enrolled. Pilot Study 2005.
- 2) Therapy Versus Placebo in Rhinophototherapy of Seasonal Allergic Rhinitis. 96 patients enrolled. 2005-2006.

ALTANA

- 1) A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Clinical Trial to Assess the Safety and Efficacy of an Intranasal Corticosteroid Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 12 Years and Older in the Cedar Allergy Season. 60 patients enrolled. Cedar 2003-2004.
- 2) A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Long Term Safety of an Intranasal Steroid in the Treatment of Perennial Allergic Rhinitis. 37 patients enrolled. 2004.
- 3) A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Clinical Trial Designed to Assess the Safety and Efficacy of a Steroid Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinitis(SAR) in Patients 6 to 11 Years of Age. 17 patients enrolled. 2006.
- 4) A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of a Steroid Nasal Aerosol in Adult and Adolescent Patients 12 years and Older with Seasonal Allergic Rhinitis (SAR). 19 patients enrolled. 2007.

AMGEN

- 1) An Open-label, Long-term Extension Study to Assess the Safety of a Psoriasis Medication in the Treatment of Psoriasis in Adult Subjects. 5 patients enrolled. 2003-2004

AMPHASTAR

- 1) A Randomized, Double-Blinded, Placebo-Controlled, Parallel Group, Multi-Center Study of the Generic Version of a Steroid Nasal Spray vs. the Reference Listed Drug, a Marketed Nasal Steroid, for Determination of Clinical Bioequivalence of Local Delivery in Patients with Seasonal Allergic Rhinitis. 80 patients enrolled. 2005-2006.

APOTEX

- 1) Bioequivalence Study of 200 mcg of a steroid nasal spray vs. 200 mcg of another steroid Nasal Spray in Patients with Seasonal Allergic Rhinitis. 40 patients enrolled. 2004.
- 2) Bioequivalence Study of a Steroid Nasal Spray vs. Another Steroid Nasal Spray in Patients with Seasonal Allergic Rhinitis. 47 patients enrolled. 2005.

- 3) Double-Blind, Multi-Centre, Placebo-Controlled, Clinical Study to Evaluate the Clinical Equivalence of a Marketed Nasal Spray vs. Another Marketed Nasal Spray for the Indication of Seasonal Allergic Rhinitis. 45 patients enrolled. 2006-2007.
- 4) A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Comparing the Bioequivalence of Synthetic Corticosteroid Aqueous Nasal Spray (APOTEX, INC.) to that of a Marketed Synthetic Corticosteroid AQ Nasal Spray (Aventis Pharmaceutical Products, Inc.) in the Treatment of Seasonal Allergic Rhinitis. 40 Patients Enrolled. 2008.

ASTRA

- 1) Double-Blind Study to Determine Efficacy and Safety of an Asthma Medication in a New Device for Adults with Mild to Moderate Asthma. 15 patients enrolled. 1995.
- 2) A Double-Blind Study to Determine the Safety and Efficacy of a New Inhaled Steroid in Patients with Non-Steroid Dependent Asthma. 15 patients enrolled. 1997.
- 3) A Double-Blind Study to Determine the Safety and Efficacy of a New Inhaled Steroid in Inhaled Steroid Dependent Asthmatics. 12 patients enrolled. 1997.

ASTRA MERCK

- 1) A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of a Once a Day Heartburn Medication. 99 patients enrolled. 1998.

ASTRA-ZENECA

- 1) Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Long-Term Treatment with a Nasal Steroid Spray in Children with Perennial Allergic Rhinitis. 9 patients enrolled. 2000.
- 2) A Placebo-Controlled, Double-Blind, Parallel Group Study of the Safety And Efficacy of 3 Doses of an Nasal Steroid Spray in Adult and Adolescent Patients with Mountain Cedar Allergic Rhinitis. 79 patients enrolled. 2001.
- 3) A Randomized, Multicenter, Placebo and Active Controlled, Single-Dose, 4-Period, Crossover Study to Evaluate the Bronchodilating Effect of an Inhaled Steroid and Long-Acting Bronchodilator Versus a Marketed Inhaled Steroid and Long-Acting Bronchodilator Verses a Plain Short-Acting Bronchodilator. 5 patients enrolled. Asthma 2003.
- 4) Crossover Study to Evaluate the Bronchodilating Effect of an Inhaled Steroid and Long-Acting Bronchodilator Versus a Marketed Inhaled Steroid and Long-Acting Bronchodilator Verses a Plain Short-Acting Bronchodilator. 6 patients enrolled. Asthma 2003.

AVENTIS

- 1) A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Assess the Safety and Tolerability of an Antihistamine Taken Twice Daily During Treatment of Children 2 through 5 Years of Age with Allergic Rhinitis. 28 patients enrolled. 2000.

- 2) A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study Assessing the Efficacy and Safety of an Oral Antihistamine Twice a Day in Pediatric Subjects (6 TO 11 YEARS) in the Treatment of Seasonal Allergic Rhinitis. 7 patients enrolled. 2000-2001.
- 3) A Phase III Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy, Safety, and Dose Response Study of a steroid Metered Dose Inhaler 50 mcg/Day, 100 mcg/Day, and 200 mcg/Day (Ex-Valve) Administered Once Daily for 12 Weeks in the Treatment of Children with Persistent Asthma. 1 patient enrolled. 2001.
- 4) A Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Randomized Study of two antihistamines in Subjects with Moderate to Severe Seasonal Allergic Rhinitis (SAR) During the Fall Allergy Season. 43 patients enrolled. 2001.
- 5) A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Assess the Safety and Tolerability of an antihistamine in Children With Allergic Rhinitis. 12 patients enrolled. 2001
- 6) A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Assess the Safety and Tolerability of an antihistamine in Children with Allergic Rhinitis. 16 patients enrolled. 2001.
- 7) A Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Randomized, Study of a marketed antihistamine 180 mg vs another marketed antihistamine HCl 10 mg in Subjects with Moderate to Severe Seasonal Allergic Rhinitis (SAR) During the Fall or Winter/Spring Allergy Season. 27 Patients Enrolled. 2002.
- 8) A Multicenter, Open-Label, Randomized, Parallel Groups Study to Assess the Long-Term Safety Performance of a marketed antihistamine Compared to a leukotriene receptor antagonist in Subjects with Asthma. 12 patients enrolled. 2002.
- 9) A Multicenter, Double-Blind, Randomized, Parallel Study Comparing the Efficacy and Safety of antihistamine 120 mg BID, antihistamine 240 mg QD and Placebo in Subjects with Perennial Allergic Rhinitis. 21 patients enrolled. 2002.
- 10) A Multicenter, Randomized, Open-Label, One Year Long-Term Safety Study of an Inhaled Corticosteroid Administered Once Daily Compared to a Marketed Inhaled Corticosteroid Administered Twice Daily For The Treatment of Children with Persistent Asthma. 1 patient enrolled. 2003.
- 11) A Multicenter, Randomized, Single-Blind, Active-Controlled, Parallel Group Study Comparing the Efficacy of Two Intranasal Corticosteroids Given for One Week for the Treatment of Seasonal Allergic Rhinitis Symptoms in Patients 12-65 Years of Age in the Spring Allergy Season. 18 patients enrolled. 2003.

- 12) A Multi-Center, Multi-National, Randomized, Double-Blind, Parallel Group Study of the Effects of 2 Inhaled Corticosteroids on Lens Opacification in Adult Subjects with Moderate to Severe Persistent Asthma. 18 Patients Enrolled. 2004.
- 13) A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of a steroid metered-dose inhaler at a daily dose of 160 µg administered for 12 weeks either in a once-daily regimen in the morning (160 µg qd AM) or in a twice-daily regimen (80 µg bid) in adults and adolescents with mild to moderate persistent asthma treated previously with inhaled corticosteroids. 18 patients enrolled. 2005.

BAKER NORTON

- 1) A Single-Dose, Dose-Ranging Efficacy Comparison of a BOI Asthma Medication and an MDI Asthma Medication. 2 patients enrolled. 2001.

BAYER

- 1) A Double-Blind Study to Compare Safety and Efficacy of Two Doses of Aerosol Medication Versus Placebo in Patients with Mild to Moderate Asthma. 13 patients enrolled. 1996.
- 2) A Randomized, Double-Blind, Parallel Group, 18-Month Evaluation of Two Dose Strengths of a Cholesterol Lowering Medication and Placebo/Another Cholesterol Lowering Medication Taken Once Daily in Patients with Hypercholesterolemia. 21 patients enrolled. 1997-1999.
- 3) A Randomized, Double-Blind, Parallel-Group Comparison of the Safety and Efficacy of Three Once Daily Doses of a PDE 4 Inhibitor with Placebo and a leukotriene receptor antagonist 10 mg Daily in Patients with Symptomatic Asthma. 21 patients enrolled. 2000.

BIOGEN

- 1) A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study of a New Antibody Drug in Subjects with Moderate to Severe Plaque Psoriasis. 7 patients enrolled. 1998.
- 2) A Randomized, Multiple-Dose, Dose-Escalation Study to Determine the Relationship of Tolerability to Dose and Plasma Concentration of a New Antibody Drug in Subjects with Moderate to Severe Plaque Psoriasis. 13 patients enrolled. 1998-1999.
- 3) A Blinded, Multiple-Dose Study to Determine the Tolerability of Repeated Courses of a New Antibody Drug in Subjects with Moderate, Moderate to Severe, and Severe Plaque Psoriasis. 6 patients enrolled. 1999.
- 4) A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Intravenous Administration of a New Antibody Drug in Subjects with Chronic Plaque Psoriasis. 10 patients enrolled. 1999-2000.

- 5) An Open-Label Study to Assess the Tolerability and Efficacy of Repeat Courses of a New Antibody Drug in Subjects with Chronic Plaque Psoriasis who have Previously Completed a Prior Psoriasis Study. 8 patients enrolled. 1999-2000.
- 6) An Open-Label Study to Determine the Safety and Efficacy of Repeat Courses of New Antibody Drug in Subjects with Chronic Plaque Psoriasis. 2 patients enrolled. 2001.

BOEHRINGER-INGELHEIM PHARMACEUTICALS

- 1) Double-Blind, Safety and Efficacy Study of a Nasal Spray in Patients with Non-Allergic Perennial Rhinitis. 35 patients enrolled. Spring 1989.
- 2) Double-Blind, Dose-Ranging, Comparison Study for Patients with Moderate to Severe Cedar Pollen Seasonal Allergic Rhinitis. 72 patients enrolled. Cedar 1990-1991.
- 3) Double-Blind, Comparison Study of a Nasal Spray on Patients with Perennial Allergic Rhinitis. 24 patients enrolled. Spring 1991.
- 4) A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess Long Term [One Year] Efficacy and Safety of an Anticholinergic Inhalation Solution Delivered by an Investigational Inhaler in Patients with Chronic Obstructive Pulmonary Disease [COPD]. 7 patients enrolled. 2007.
- 5) Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled Long-Acting Anticholinergic Bronchodilator, each in fixed dose Combination with 5 µg Orally Inhaled Long-Acting Anticholinergic Bronchodilator (Delivered by a Soft Mist Inhaler) Compared with 5 µg Orally Inhaled Long-Acting Anticholinergic Bronchodilator Monoprotocol (Delivered by a Soft Mist Inhaler) in Patients with COPD. 7 Patients Enrolled. 2008

BURROUGHS WELLCOME

- 1) Two Protocols on an Antihistamine for Safety and Efficacy. 100 patients enrolled. 1983-1984.
- 2) Comparison Study of a New Combination Antihistamine/Decongestant to its Component Parts in Seasonal Allergic Rhinitis. 112 patients enrolled over a 5-week period. Cedar 1989-1990.
- 3) Double-Blind, Comparison Study of an Antihistamine for the Treatment of Seasonal Allergic Rhinitis Symptoms. 53 patients enrolled. Fall 1990.
- 4) A Comparison Study for Patients with Seasonal Allergic Rhinitis Symptoms during Cedar Season. 120 patients enrolled. Cedar 1990-1991.
- 5) A Comparison Study of a New Combination Antihistamine/ Decongestant and Seldane Tablets for Onset of Action and Effectiveness Across 1 week of Treatment in Patients with Seasonal Allergic Rhinitis Symptoms. 53 patients enrolled. Cedar 1991-1992.

CAPNIA

- 1) A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide in the Treatment of Seasonal Allergic Rhinitis. 40 Patients Enrolled. Fall 2008.

CIBA

- 1) Open-Label Study to Evaluate Patient Use and Tolerability of a Once-A-Day Antihistamine/Decongestant Combination. 30 patients enrolled. 10/1988.
- 2) Single-Blind Study to Compare Patient Use and Overall Subjective Evaluation of Product Performance of Several Different Antihistamines on Seasonal and Perennial Rhinitis. 100 patients enrolled. Fall 1989.
- 3) Antihistamine Comparison Study for Patients with Allergic Rhinitis during Ragweed Season. 40 patients enrolled. Fall 1990.
- 4) Study to Determine the Safety, Tolerability, and Efficacy of an IV Medication in Patients with Seasonal Allergic Rhinitis during the Mountain Cedar Season. 44 patients enrolled. Cedar 1994-1995.
- 5) A Double-Blind Study Comparing the Safety, Tolerability, and Efficacy of a Dry Powder Inhalation for Asthma in Patients with Mild to Moderate Asthma. 20 patients enrolled. 1995.
- 6) A Double-Blind Study Comparing Safety, Tolerability and Efficacy of Different Doses of Drug Powder Capsules for Inhalation Versus Placebo when Treating Patients with Mild to Moderate Asthma. 16 patients enrolled. 1996.
- 7) A Double-Blind Study to Determine the Efficacy, Safety, Tolerability, Pharmacokinetics and Biologic Activity of Different Dose Levels of an Intravenous Medication Given every 2 Weeks for 6 Times in Patients with Mild to Moderate Perennial Allergic Asthma. 12 patients enrolled. 1996.
- 8) A Phase I Study to Determine Pharmacokinetics and Pharmacodynamics of a Single Dose of Medication Given Intravenously or Subcutaneously to Healthy Atopic Subjects. 26 patients enrolled. 1996.

CLAY-PARK

- 1) An Investigator-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Demonstrate the Safety and Bioequivalence of a steroid Nasal Spray Compared with a marketed steroid nasal 55 mcg in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis (SAR). 52 patients enrolled. 2005.

COBALIS

- 1) A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Of The Safety and Efficacy Of Pre-Seasonal Sublingual vitamin Lozenges On Moderate To Moderately Severe Allergic Rhinitis In Humans. 90 patients enrolled. 2004-2005.

COLLEGIUM

- 1) A Randomized, Open Label, Placebo Controlled, Parallel-Group Study to Compare the Safety and Efficacy of Two Marketed Antihistamines Administered Together with a Marketed Antihistamine Administered Alone in Adult Subjects with Seasonal Allergic Rhinitis. 20 patients enrolled. 2006.

CRITERIUM

- 1) A Multi-Center, Three Arm, Parallel Group, Partially Blind, Placebo-Controlled, Randomized Study of the Bioequivalence and Efficacy of a Steroid Nasal Spray Compared to a Marketed Steroid Nasal Spray in Patients with Seasonal Allergic Rhinitis. 52 patients enrolled. Spring 2006.

DEY

- 1) A Placebo and Active-Controlled, Double-Blind, Parallel-Group Comparison of Two Nasal Sprays in Seasonal Allergic Rhinitis. 120 patients enrolled. 1998-1999.
- 2) A Double-Blind, Double-Dummy, Randomized, Placebo Controlled Multicenter Study to Assess the Safety and Efficacy of a steroidal Nasal Spray 0.042% in Adolescent and Adult Patients with Seasonal Allergic Rhinitis. 30 patients enrolled. 2001.
- 3) A Double-Blind, Double-Dummy, Randomized, Placebo Controlled Multicenter Study to Assess the Safety and Efficacy of a steroidal Nasal Spray in Adolescent and Adult Patients With Seasonal Allergic Rhinitis Due to Mountain Cedar Allergies. 105 patients enrolled. 2001-2002.

DURA

- 1) An Open-Label, Multiple-Dose, Multi-Center Study to Evaluate the Safety of an inhaled steroid and Reliability of the "To Be Marketed" Dry Powder Inhaler in Patients with Asthma. 18 patients enrolled. 1999-2000.

DYNAVAX

- 1) A Phase IIb, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Subcutaneously Administered Immunotherapy Medication in Ragweed-Allergic Adults" 17 patients enrolled. 2004.
- 2) A Phase III, Non-Pivotal, Double-Blind, Randomized Study of the Efficacy, Safety and Tolerability of Subcutaneously Administered Immunotherapy Medication Plus Antihistamine and Decongestant Versus Antihistamine and Decongestant Alone in Ragweed Allergic Children. 23 patients enrolled. 2005.

- 3) A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Dose-Regimen Study of the Efficacy and Safety of a Subcutaneously Administered Immunotherapy in Ragweed-Allergic Rhinitis Adults. 34 patients enrolled. 2006.

EMERGENT BIOSOLUTIONS

- 1) Immunogenicity Study of a Three-Dose Subcutaneous Vaccine for Post-Exposure Prophylaxis in Healthy Adults. 40 patients enrolled. 2006.

FISONS PHARMACEUTICALS

- 1) A Pre-Season, Dose-Ranging, Double-Blind, Placebo-Controlled Group Comparative Study of a New Nasal Spray in Patients with Seasonal Allergic Rhinitis Caused by Cedar Pollen. 72 patients enrolled. Cedar 1991-1992.

GENDERM

- 1) A Double-Blind Study Comparing Two Doses of a Nasal Spray vs Placebo for the Treatment of Seasonal Allergic Rhinitis during the Mountain Cedar Season. 60 patients enrolled. Cedar 1995-1996.

GLAXO/GLAXO WELLCOME

- 1) A Double-Blind Comparison Study of the Efficacy and Safety of 2 Steroid Nasal Sprays on Seasonal Allergic Rhinitis during the Mountain Cedar Season. 50 patients enrolled. Cedar 1988-1989.
- 2) A Double-Blind Comparison Study of the Efficacy and Safety of 2 Nasal Steroids in Adolescent Patients with Seasonal Allergic Rhinitis. 24 patients enrolled. Spring 1989.
- 3) A Double-Blind Comparison Study of a Topical Steroid for Patients with Seasonal Allergic Rhinitis in the Mountain Cedar Season. 45 patients enrolled. Cedar 1990.
- 4) A Double-Blind Comparison Study of an Inhaled Steroid in Adolescent and Adult Patients with Moderate Asthma. 28 patients enrolled. Summer 1991-Spring 1992.
- 5) A Double-Blind Comparison Study of a Topical Steroid for Patients with Seasonal Allergic Rhinitis in the Spring Allergy Season. 32 patients enrolled. Spring 1992.
- 6) A Double-Blind Comparison Study for Efficacy of a Steroid Nasal Spray and an Oral Steroid in Patients with Seasonal Allergic Rhinitis during the Mountain Cedar Allergy Season. 65 patients enrolled. Cedar 1992-1993.
- 7) Randomized, Double-Blind, Parallel-Group Trial to Assess Efficacy of a New Inhaled Steroid in Adult Patients with Moderate Asthma. 13 patients enrolled. Fall 1993.
- 8) Randomized, Double-Blind, Comparative Trial of a New Inhaled Steroid vs Placebo in Adolescent and Adult Patients with Mild to Moderate Asthma. 30 patients enrolled. Summer 1994.

- 9) Double-Blind, Comparative Trial of an Inhaled Steroid in Adolescent and Adult Subjects with Mild to Moderate Asthma. 17 patients enrolled. Summer/Fall 1995.
- 10) Twelve Week, Double-Blind Comparative Study of a Long Acting Asthma Medication for Adults and Adolescents with Mild to Moderate Asthma. 24 patients enrolled. Summer/Fall 1995.
- 11) A Double-Blind, Parallel-Group Comparison of the Efficacy and Safety of a Nasal Spray vs an Oral Antihistamine for 2 weeks in Patients with Seasonal Allergic Rhinitis. 120 patients enrolled. Winter 1995.
- 12) A Double-Blind Study to Evaluate the Safety and Efficacy of Albuterol in a New Propellant in Patients with Asthma. 16 patients enrolled. 1996-1997.
- 13) A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Evaluation of an Anti-Ulcer Drug for the Reduction of Severity or Prevention of Meal-Induced Heartburn. 52 patients enrolled. Spring 1997.
- 14) A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Clinical Trial Assessing the Safety and Efficacy of Albuterol via a New Device Versus Albuterol via the MDI Versus Placebo in Pediatric Subjects Aged 4-11 years with Asthma. 9 patients enrolled. Spring/Summer 1997.
- 15) A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled, Parallel-Group Comparison of Two Different Aqueous Nasal Sprays in Patients with Seasonal Allergic Rhinitis. 30 patients enrolled. Fall 1997.
- 16) A Single-Blind, Randomized, Parallel-Group Comparison of the Efficacy and Safety of an Aqueous Nasal Spray vs a Non-Steroidal Prophylactic Nasal Spray vs Placebo for Four Weeks in Subjects with Seasonal Allergic Rhinitis. 24 patients enrolled. Fall 1997.
- 17) A Randomized, Double-Blind, Multi-Center Comparison of the Efficacy and Safety of a 5- or 10-Day Course of an Antibiotic and a 14-Day Course of a different antibiotic in the Treatment of Patients with Acute Bacterial Maxillary Sinusitis. 13 patients enrolled. Spring 1998.
- 18) A Placebo and Active-Controlled, Double-Blind, Parallel-Group Comparison of Two Nasal Sprays in patients with Seasonal Allergic Rhinitis. 120 patients enrolled. 1998.
- 19) A Randomized, Double-Blind, Parallel-Group Trial of an Inhaled Asthma Drug with New Propellant in Adolescent and Adult Subjects with Asthma. 11 patients enrolled. 1999.
- 20) A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of an Inhaled Medication Administered Twice Daily for Five Days in the Treatment of Influenza in Patients 12 Years or Over Diagnosed with Asthma or Chronic Obstructive Pulmonary Disease. 1 patient enrolled. 1999.

- 21) A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of an Inhaled Medication Administered Twice Daily for Five Days in the Treatment of Symptomatic Influenza A and B in Children Ages 5-12. 19 patients enrolled. 1999.
- 22) A Randomized, Double-Blind, Active-Controlled, Parallel-Group, 12-Week Trial Evaluating the Safety and Efficacy of an Asthma DISKUS Combination Product BID Compared with a long-acting Beta2-agonist mg via DISKUS BID and an inhaled steroid via DISKUS BID in Symptomatic Adult and Adolescent Subjects with Asthma on Short-Acting Beta2-Agonist Therapy. 10 patients enrolled. 1999-2000.
- 23) A Multi-Center, Randomized, Double-Blind, Parallel-Group Study Examining the Effect of an Aqueous Nasal Spray QD in Subjects with Sinus Pain and Pressure Associated with Nasal Congestion due to Allergic Rhinitis. 61 patients enrolled. Cedar 2000.
- 24) A Double-Blind, Double-Dummy, Randomized, Parallel Group Comparison of a Nasal Steroid Spray, Placebo, and an Antihistamine Administered (No More Than Once Daily) As-Needed in Subjects with Seasonal Allergic Rhinitis. 30 patients enrolled. 2000.
- 25) A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of an Inhaled Antiviral Administered Once a Day for 28 Days in the Prevention of Symptomatic Influenza A and B Viral Infections in Community-Dwelling High Risk Subjects Aged ≥ 12 Years. 96 patients enrolled. 2000-2001.
- 26) A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Two-Week Study Assessing the Efficacy of a aqueous steroid nasal spray Versus leukotriene receptor antagonist 10 mg QD in Subjects > 15 years Old with Seasonal Allergic Rhinitis. 180 patients enrolled. 2001-2002.

GLAXO-SMITHKLINE

- 1) A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of a Four-Week Course of Nasal Steroid Spray on Ocular Symptoms Commonly Associated with Seasonal Allergic Rhinitis. 45 patients enrolled. Spring 2001.
- 2) An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of a Combination Inhaled Steroid and Long-Acting Bronchodilator with Counter in Asthma or COPD Subjects at Least 12 Years of Age. 9 patients enrolled. 2003.
- 3) An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of a Short-Acting Bronchodilator with Counter in Asthma or COPD Subjects at Least 4 Years of Age. 12 patients enrolled. 2003.
- 4) A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Corticosteroid of Several Doses for 14 days in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis During the Cedar Allergy Season. 95 patients enrolled. Cedar 2003-2004.

- 5) A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of an intranasal steroid Aqueous Nasal Spray 100 mcg for 2 Weeks in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis. 59 patients enrolled. 2004-2005.
- 6) A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of an intranasal steroid Aqueous Nasal Spray 100 mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age) with Perennial Allergic Rhinitis (PAR). 6 patients enrolled. 2005.
- 7) A Randomized, Double-Blind, Parallel Group, 52-week Study to Compare the Effect of the an inhaled steroid/long acting beta 2 agonist Combination Product 250/50mcg BID with Long acting beta 2 agonist 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD). 9 patients enrolled. 2005.
- 8) A Comparison of a steroid Nasal Spray versus Oral Antihistamine in the Treatment of Seasonal Allergic Rhinitis. 97 patients enrolled. 2006-2007.
- 9) A Multi-Center, No Drug Treatment, Cross-Sectional Survey Study to Develop and Validate the Rhinitis Control Assessment Questionnaire (RCAQ) in Adult and Adolescent Subjects 12 Years of Age and Older with Non-Infectious Allergic Rhinitis. 22 patients enrolled. 2006-2007.
- 10) A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy, Patient Preference and Experience of Once-Daily, Intranasal Administration of a Steriod Nasal Spray and a higher dose of Steroid Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis. 16 patients enrolled. 2007.

HI-TECH

- 1) A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of a steroid Nasal Spray with a marketed steroid Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis. 29 patients enrolled. 2004.

HOECHST MARION ROUSSEL

- 1) A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Study Comparing the Efficacy and Safety of Four Dosage Strengths of an Antihistamine in the Treatment of Chronic Idiopathic Urticaria. 12 patients enrolled. 1997.
- 2) A Double-Blind, Randomized, Placebo-Controlled, Parallel-Study Comparing the Efficacy and Safety of Two Doses of an Antihistamine Given QD in the Treatment of Fall Seasonal Allergic Rhinitis. 52 patients enrolled. Fall 1997.
- 3) A Double-Blind, Randomized, Placebo-Controlled, Parallel-Study Comparing the Efficacy and Safety of Three Dosage Strengths of a Twice a Day Oral Antihistamine in Pediatric

Patients (Ages 6 to 11 years) in the Treatment of Seasonal Allergic Rhinitis. 20 patients enrolled. Fall 1997.

- 4) A Double-Blind, Randomized, Parallel-Study Comparing the Efficacy and Safety of Three Doses of an Oral Antihistamine in the Treatment of Perennial Allergic Rhinitis. 24 patients enrolled. Spring 1999.

HOFFMANN-LAROCHE

- 1) Comparison Study of the Safety and Anti-Hypertensive Effects of a New ACE Inhibitor. 24 patients enrolled. Fall 1989.
- 2) A Double-Blind Comparison Study of a New Oral Medication for the Treatment of Obesity. 41 patients enrolled. Summer 1993.

IMMUTECH PHARMACEUTICALS

- 1) Safety and Efficacy Study on Subcutaneously Injected HEPP (Human IgE Pentapeptide) in the Treatment of Seasonal Allergic Rhinitis. 20 patients enrolled. 1984.
- 2) Phase III Clinical Trial on HEPP Intranasal Solution and Seasonal Allergic Rhinitis. 40 patients enrolled over a 3-week period. Spring 1986.
- 3) Phase III Clinical Trial on HEPP Intranasal Solution and Seasonal Allergic Rhinitis, 3 Month Safety and Efficacy Study. 50 patients enrolled. Fall 1986.
- 4) HEPP Ophthalmic Solution Onset of Action on Seasonal Allergic Conjunctivitis, Safety and Efficacy Study. 12 patients enrolled. Cedar 1987.

IMMUNEX

- 1) Phase II Safety and Efficacy Study of a New Nebulized Asthma Medication. 10 patients enrolled. 2000-2001.
- 2) Phase II Safety and Efficacy Study of a New Nebulized Asthma Medication in Asthma Patients Using Inhaled Corticosteroids. 2 patients enrolled. 2001.
- 3) A Multicenter Dose Ranging Study of the Safety and Efficacy of an injectable psoriasis medication in Psoriasis. 10 patients enrolled. 2002.

INSPIRE PHARMACEUTICALS, INC.

- 1) A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Safety, Efficacy, and Tolerability Study of Two Doses of a nasal antihistamine vs. Placebo in Subjects with Seasonal Allergic Rhinitis. 89 patients enrolled. 2006-2007.
- 2) A Phase 3 Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple Dose Safety and Efficacy Study of an Intranasal Antihistamine vs. Placebo in Subjects with Seasonal Allergic Rhinitis. 83 patients enrolled. 2007-2008.

IVAX

- 1) A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Compare the Safety and Efficacy of a steroid Aqueous Nasal Spray to another steroid Nasal Spray and Placebo in Patients with Seasonal Allergic Rhinitis. 93 patients enrolled. 2001-2002.
- 2) A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Safety and Efficacy of an Intranasal Corticosteroid Compared to a Marketed Intranasal Corticosteroid and Placebo in Patients with Ragweed-Induced Seasonal Allergic Rhinitis. 32 patients enrolled. Fall 2003.

JANSSEN PHARMACEUTICAL COMPANY

- 1) The Clinical Evaluation of the Safety and Efficacy of an antihistamine/decongestant Combination in the Treatment of Seasonal Allergic Rhinitis. 75 patients enrolled. Fall 1987.
- 2) Safety and Efficacy Study of a New Antihistamine on Seasonal Allergic Rhinitis in Children. 45 patients enrolled. Fall 1988.
- 3) Clinical Study to Determine the Efficacy of the Pseudoephedrine Component of an antihistamine/decongestant Combination at the End of the 2-Week Dosing Interval. 75 patients enrolled. Fall 1991.
- 4) Clinical Study to Determine the Safety and Efficacy of an antihistamine/decongestant Combination in Comparison to Seldane-D and Placebo in the Treatment of Seasonal Allergic Rhinitis. 75 patients enrolled. Cedar 1991-1992.
- 5) A Double-Blind Comparison Study for the Safety and Efficacy of an antihistamine/decongestant combination and another antihistamine/decongestant combination in the Treatment of Seasonal Allergic Rhinitis. 36 patients enrolled. Fall 1992.
- 6) Double-Blind Nasal Spray Comparison Study for Patients with Seasonal Allergic Rhinitis during the Fall. 50 patients enrolled. Fall 1993.
- 7) Study to Determine the Safety and Efficacy of a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis during the Mountain Cedar Season. 100 patients enrolled. Cedar 1994/95.
- 8) A Study to Determine the Safety of a Nasal Spray Used Over 6 Months. 57 patients enrolled. Spring 1995.

MAP

- 1) A randomized, double blind, placebo controlled, 3 arm, parallel group, phase 2 study investigating the efficacy, tolerability and pharmacokinetics of a nebulized steroid in asthmatic children and adolescents over 6 weeks. 13 patients enrolled. 2006.

- 2) A randomized, double blind, placebo controlled, parallel group, study investigating the safety and efficacy over 12 weeks treatment period of a Nebulized Corticosteroid in asthmatic infants and children 12 months to 8 years of age. 3 Patients Enrolled. 2008.
- 3) A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of an Inhaled Medication in Adult Migraineurs for a Single Migraine Followed by Open -Label Extensions to 26/52 Weeks. Still Enrolling. 2008.
- 4) A randomized, double blind, active controlled, Phase 3 extension study investigating the safety and efficacy over 40 weeks of 2 doses of a Nebulized Corticosteroid in asthmatic infants and children 12 months to 8 years of age. 2 Patients Enrolled. 2008.

MCNEIL CONSUMER PRODUCTS

- 1) A Comparison Study to Evaluate the Safety and Efficacy of over the counter allergy medications, a prescription antihistamine and Placebo in Patients with Seasonal Allergic Rhinitis. 40 patients enrolled. Fall 1992.
- 2) Double-Blind Comparison Study of a New Antihistamine for Patients with Allergic Rhinitis to Mountain Cedar Pollen. 65 patients enrolled. Cedar 1993-1994.
- 3) A Randomized, Double-Blind, Multi-Center Study of the Efficacy and Safety of an Over the-Counter Allergy Medication Compared with a prescription allergy medicine in the Treatment of Seasonal Allergic Rhinitis. 40 patients enrolled. Spring 1998.
- 4) An Open-Label Study of an NSAID/decongestant Suspension in Children. 10 patients enrolled. Summer 1999.

MEDA

- 1) Randomized, Double-Blind Trial of a Combination Antihistamine and Steroid Nasal Spray Compared to Placebo, a Marketed Intranasal Antihistamine, and an Intranasal Steroid in the Treatment of Patients with Seasonal Allergic Rhinitis. 28 Patients Enrolled. 2008.
- 2) Randomized, Double-Blind, Double-Dummy Trial of Two Sustained Release Formulations of a Muscle Relaxant Compared to Placebo in Patients with Acute, Painful Musculoskeletal Spasm of the Lower Back. Still Enrolling. 2008.
- 3) Randomized, Double-Blind Trial of the Combination of an Antihistamine Nasal Spray and Intranasal Corticosteroid Compared to Placebo, Antihistamine Nasal Spray, and Intranasal Corticosteroid in the Treatment of Patients with Seasonal Allergic Rhinitis. 27 Patients Enrolled. Fall 2008.
- 4) Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of a Nasal Antihistamine in Subjects with Seasonal Allergic Rhinitis. 78 Patients Enrolled. Cedar 2008-2009.

MEDICINOVA

- 1) A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of a Novel Leukotriene Inhibitor in Subjects with Mild to Moderate Asthma. 3 patients enrolled. 2007.

MEDIMMUNE

- 1) A Prospective, Double-Blind, Randomized Trial To Demonstrate Equivalent Immunogenicity Of inactivated flu vaccine and live attenuated flu vaccine In Healthy Participants Ages 5 Through 49 Years. 32 patients enrolled. 2004.
- 2) A Randomized, Double-Blind Trial To Assess The Safety and Relative Efficacy Of a live attenuated influenza vaccine Against Inactivated Influenza Vaccine in Children 6-59 Months of Age. 34 patients enrolled. 2004.
- 3) A Phase 2 Open-Label, Single-Arm Trial to Evaluate the Shedding and Safety of Vaccine Administered to Children 6 to <60 Months of Age. 20 patients enrolled. 2006.

MEDPOINTE

- 1) A Randomized, Double-Blind, Placebo-Controlled Trial of antihistamine Nasal Spray, and an oral antihistamine in Patients With Seasonal Allergic Rhinitis. 31 patients enrolled. 2002.
- 2) A Randomized, Double-Blind, Placebo-Controlled Trial of antihistamine nasal spray 137 mcg and antihistamine nasal spray 137 mcg plus oral antihistamine in Patients With Seasonal Allergic Rhinitis. 15 patients enrolled. 2003.
- 3) A Randomized, Double-Blind, Placebo-Controlled Trial of antihistamine nasal spray 137 mcg at a Dosage of One Spray per Nostril Twice Daily in Patients With Seasonal Allergic Rhinitis. 24 patients enrolled. 2003.
- 4) Randomized, Double-Blind Trial of an antihistamine Nasal Spray compared to an oral antihistamine in Patients With Seasonal Allergic Rhinitis. 24 patients enrolled. 2004.
- 5) Randomized, Double-Blind trial of an antihistamine Nasal Spray Compared to an oral antihistamine in Patients with Seasonal Allergic Rhinitis. 14 patients enrolled. 2005.
- 6) A Randomized, Double-Blind, Double-Dummy Trial of the Combination of a Marketed Antihistamine Nasal Spray and a Marketed Steroid Nasal Spray Compared to Either Product Alone in the Treatment of Patients with Allergy to Texas Mountain Cedar. 35 patients enrolled. 2005-2006.
- 7) Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of a Nasal Antihistamine in Patients with Seasonal Allergic Rhinitis. 22 patients enrolled. 2006.
- 8) Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Two Intranasal Antihistamines in Patients with Perennial Allergic Rhinitis. 34 patients enrolled. 2007.
- 9) Active-Controlled Trial of the Safety and Tolerability of an Intranasal Antihistamine in Patients with Perennial Allergic Rhinitis. 31 patients enrolled. 2007.

- 10) Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Two Intranasal Antihistamines Compared to Placebo in Patients with Seasonal Allergic Rhinitis. 27 patients enrolled. 2007.
- 11) Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of an Intranasal Antihistamine in Subjects with Seasonal Allergic Rhinitis. 88 patients enrolled. 2007-2008.
- 12) Randomized, Double-Blind Trial of an Intranasal Antihistamine Nasal Spray Compared to Placebo, a Marketed Intranasal Antihistamine, and an Intranasal Steroid in the Treatment of Patients with Seasonal Allergic Rhinitis. 92 patients enrolled. 2007-2008

MERCK & CO.

- 1) A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Effect of an Oral Once a Day Asthma Medication to Inhaled Steroid in Adults. 16 patients enrolled. Fall 1997.
- 2) A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Compare Concomitant Use of a Leukotriene Inhibitor and Loratadine with Intranasal Steroid in Patients with Seasonal Allergic Rhinitis. 50 patients enrolled. Spring 1998.
- 3) A Multi-Center, Double-Blind, Randomized Study Comparing the Clinical Effect of Concomitant Oral Asthma and Antihistamine with Asthma, Antihistamine and Inhaled Steroid in Patients with Chronic Asthma. 12 patients enrolled. 1998.
- 4) A Multi-Center, Double-Blind, Placebo-Controlled Study of the Clinical Effect of a New Nebulized Asthma Drug in Patients with Chronic Asthma. 2 patients enrolled. 1998-1999.
- 5) A Multi-Center, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Antihistamine in Patients with Seasonal Allergic Rhinitis. 40 patients enrolled. Fall 1999.
- 6) A Randomized, Double-Blind, Multi-Center Study to Evaluate the Effect of Adding Either a leukotriene receptor antagonist or long acting beta 2 agonist to an Inhaled Corticosteroid In Adult Asthmatics. 8 patients enrolled. 2000.
- 7) A Multi-Center, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Antihistamine in Patients With Seasonal Allergic Rhinitis. 89 patients enrolled. Spring 2000.
- 8) A Multi-Center, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination leukotriene receptor antagonist/Antihistamine in Patients With Seasonal Allergic Rhinitis. 89 patients enrolled. Spring 2000.

- 9) A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of a leukotriene receptor antagonist in Patients With Seasonal Allergic Rhinitis. 31 patients enrolled. Fall 2000.
- 10) A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing a leukotriene receptor antagonist with Placebo in Pediatric Patients Aged 2 Through 14 Years With Seasonal Allergic Rhinitis. 26 patients enrolled. Spring 2001.
- 11) Safety and Efficacy of a Rotavirus Vaccine in Healthy Infants. 39 patients enrolled. 2001.
- 12) A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effects of a leukotriene receptor antagonist in Patients With Seasonal Allergic Rhinitis Over a 4-Week Treatment Period-Fall 2001. 35 patients enrolled. 2001.
- 13) A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of a leukotriene receptor antagonist in Patients with Perennial Allergic Rhinitis. 29 patients enrolled. 2001.
- 14) A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of a COX 2 inhibitor in Patients with Osteoarthritis or Rheumatoid Arthritis. 32 patients enrolled. 2002-2003.
- 15) A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of an Investigational Medication in Patients with Seasonal Allergic Rhinitis-a Pilot Study During the Fall Season. 28 patients enrolled. 2003.
- 16) A Multicenter, Double-Blind, Randomized Study Investigating the Clinical Effect of an Oral Leukotriene Inhibitor on Allergic Rhinitis in Patients with Seasonal Allergic Rhinitis and Chronic Asthma – Spring Season. 18 patients enrolled. 2003.
- 17) A Double-Blind, Randomized, Placebo-Controlled, Multi-center, 2-Period Crossover Study to Evaluate the Effects of Single Dose of an Oral leukotriene Inhibitor on Exercise Induced Bronchospasm. 4 patients enrolled. 2003.
- 18) A Double-Blind, Randomized, Placebo-Controlled, Multi-Center, 2-Period, Crossover Study to Evaluate the Effects of a Single Dose of Montelukast on Exercise-Induced Bronchospasm. 3 patients enrolled. 2004.
- 19) A Multicenter, Randomized, Double-blind, Placebo-Controlled Parallel Group 8-Week Study to Evaluate the Efficacy and Safety of Chewable Leukotriene Inhibitor When Initiated at the Start of the School year in Pediatric Patients With Chronic Asthma. 9 patients enrolled. 2006.

MERRELL DOW/MARION MERRELL DOW

- 1) Safety and Efficacy Study of an Antihistamine for Patients with Seasonal Allergic Rhinitis. 60 patients enrolled. Cedar 1990-1991.

- 2) A Double-Blind Comparison Study of the Safety and Efficacy of 3 Different Doses of Seldane to Placebo during a One-Week Treatment Period in Patients with Spring Seasonal Allergies. 62 patients enrolled. Spring 1993.
- 3) Double-Blind, Antihistamine Comparison Study for Patients with Allergic Rhinitis in Fall. 65 patients enrolled. Fall 1993.
- 4) Double-Blind Comparison Study of an Antihistamine for Patients with Spring Allergic Rhinitis. 70 patients enrolled. Spring 1994.
- 5) A Randomized, Double-Blind Comparative Study to Evaluate the Safety and Tolerability of a New Antihistamine vs Placebo in Normal, Healthy Subjects. 20 patients enrolled. Summer 1994.
- 6) A Randomized, Double-Blind Study Comparing Multiple Strengths of a New Antihistamine vs Placebo in Patients with Fall Seasonal Allergic Rhinitis. 58 patients enrolled. Fall 1994.
- 7) Safety and Tolerance Study of an Antihistamine Used by Normal Healthy Patients. 32 patients enrolled. Spring 1995.

MURO

- 1) Double-blind, Placebo Controlled, Randomized, Parallel Group Study of Four Doses of a New Steroid Nasal Spray with a Marketed Steroid Nasal Spray as an Open Active Control in the Treatment of Adults and Adolescents with Allergic Rhinitis Induced by Grass Pollen. 32 patients enrolled. Spring 2001.

NOVARTIS

- 1) A 7-Month Double-Blind, Randomized, Parallel-Group, Parallel-Controlled, Multicenter Trial with a 5-Month Open-label Extension Period to assess safety and Tolerability, Steroid-reduction, Pharmacodynamics of a Subcutaneous Anti-IGE Medication in Children (6-12 years) with Allergic Asthma Requiring Daily Treatment With Inhaled Corticosteroid. 17 patients enrolled. 1998-1999.
- 2) An Open-Label Extension to Provide Continuation of an Anti-IGE Medication to Children with Allergic Asthma who Participated in the Above One-Year Study. 3 patients enrolled. 1999.
- 3) An Open-Label Extension to Provide Continuation of rhuMAb-E25 Treatment to Children with Allergic Asthma who Participated in the One-Year Study. 17 patients enrolled. 2001.
- 4) A Randomized, Multicenter, Placebo-controlled, Double-blind, Parallel Group Study to Evaluate the Safety of Treatment a Long-Acting Bronchodilator as Evaluated by Holter Monitoring, in Adult Patients with Chronic Obstructive Pulmonary Disease (COPD). 6 patients enrolled. 2003.

- 5) A randomized, double-blind, placebo-controlled, parallel group, multi-center, multiple dose (7 days) dose-ranging study, to assess the efficacy and safety of 4 doses of QAB149 (50, 100, 200, & 400 µg) delivered via a multiple dose inhaler, and 1 dose of QAB149 (400 µg) delivered via a single dose inhaler in patients with chronic obstructive pulmonary disease (COPD). 6 patients enrolled. 2004.
- 6) A 26-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of two doses of an investigational long-acting bronchodilator in patients with chronic obstructive pulmonary disease using a marketed long-acting bronchodilator and open label inhaled anticholinergic as active controls. 5 patients enrolled. 2007.

ONO

- 1) A Four-Week, Double-Blind, Placebo-Controlled Exploratory Evaluation of FEV_{1.0} Changes and Safety of a New Investigational Medication in Patients with Chronic Obstructive Pulmonary Disease (COPD).” 8 patients enrolled. 2004.

PERRIGO

- 1) A Blinded, Randomized, Vehicle-Controlled, Parallel-Group Multicenter Study to Demonstrate the Safety and Bioequivalence of a Steroid Nasal Spray Compared with a Marketed Steroid Nasal Spray in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR). 70 patients enrolled. 2007.

PHARMAXIS

- 1) A Phase III Multicenter Study to Demonstrate the Sensitivity and Specificity of a Drug Challenge as Compared with another drug Challenge to Predict Bronchial Hyperresponsiveness as Manifested by a Positive Exercise Challenge in Subjects Presenting with Signs and Symptoms Suggestive of Asthma but Without a Definitive Diagnosis. 34 patients enrolled. 2006.

PFIZER

- 1) A Multi-Center, Double-Blind, Comparative Study of the Efficacy and Safety of a Once Daily Antihistamine vs. Claritin and Placebo in the Treatment of Chronic Idiopathic Urticaria. 10 patients enrolled. 1997.
- 2) An Open label, Multi-Center study of the Efficacy, Safety and Effect on Quality of Life of a Once Daily Antihistamine Syrup in the Treatment of Seasonal Allergic Rhinitis in Children. 5 patients enrolled. Fall 1997.
- 3) Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Eight Week Study of Efficacy and Safety of a New Inhaled Asthma Drug in Adults with Persistent Asthma. 12 patients enrolled. 1998.
- 4) A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy, Safety and Effect on Quality of Life, Work Productivity and Activity Impairment of an Oral Antihistamine vs. Placebo in the Treatment of Seasonal Allergic Rhinitis. 20 patients enrolled. Fall 1998.

- 5) Phase IIA Multi-Center, Randomized, Double-Blind, Double-Dummy, Active and Placebo-Controlled, Parallel Group, Dose-Response Study of the Efficacy, Safety, and Tolerability of Six Weeks Oral Dosing with a New Asthma Drug Compared to an Oral leukotriene Inhibitor and Placebo in Adults with Persistent Asthma. 10 patients enrolled. 1999.
- 6) A Randomized, Double-Blind, Parallel-Group, Multi-Center Study of the Efficacy and Safety of Antihistamine/Decongestant Combination vs Antihistamine /Decongestant Combination vs Placebo in the Treatment of Subjects Twelve Years and Older with Seasonal Allergic Rhinitis. 36 Patients Enrolled. Spring 2000.
- 7) A Clinical Efficacy Comparison of an OTC antihistamine, prescription antihistamine, and Placebo in Seasonal Allergic Rhinitis. 48 patients enrolled. 2002.
- 8) A Clinical Efficacy Study of Two Doses of Benadryl® Compared to Placebo in Seasonal Allergic Rhinitis. 86 patients enrolled. 2002-2003.
- 9) Evaluation of Nasal Congestion Clinical Efficacy for two doses of a Marketed, Oral Antihistamine in Seasonal Allergic Rhinitis: A Randomized, Double-Blind, Placebo and a marketed decongestant Controlled Study. 57 patients enrolled. 2007.

PHARMACIA & UPJOHN

- 1) An Evaluation of Safety and Tolerance of a Medication Following the Administration of a Nasal Solution to Pediatric Subjects. 20 patients enrolled. Spring 1999.

PHARMAKINETICS LABORATORIES, INC.

- 1) A Drug Interaction and Efficacy Study of a Calcium Channel Blocker and Diuretic on Hypertension. 31 patients enrolled.

PROCTOR & GAMBLE

- 1) A Multi-Center, Double-Blind, Randomized, Single-Dose, Placebo-Controlled Study to Investigate the Efficacy and Safety of Two Doses of a Proton Pump Inhibitor in Treating Heartburn Symptoms Following a Provocative Meal. 88 patients enrolled. 1999.

REGENERON

- 1) Phase III, Double-Blind, Randomized, Placebo-Controlled Study of a new weight loss drug in Severely Obese Subjects. 38 patients enrolled. 2001
- 2) A Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of a weight loss medication Including 3 Months of Initial Drug Dosing, a 9 Month Off-Drug Treatment Period, and a 1 Month Re-Exposure in Overweight and Obese Subjects. 38 patients enrolled. 2002.

A.H. ROBINS

- 1) Dose-Ranging Antihypertensive Trial for a New Beta-Blocker. 33 patients enrolled. 1986.

- 2) Anihypertensive Comparison Study of Safety and Efficacy of a New Beta-Blocker. 30 patients enrolled. 1987.

RHONE POULENC RORER

- 1) Patient Preference and Sensory Comparisons of Two Inhalers with Different Propellants in Asthmatic Patients. 30 patients enrolled. 1998.

RORER CENTRAL RESEARCH/RHONE-POULENC RORER

- 1) Efficacy and Comparison Study of a New Nasal Steroid vs an Injected Steroid on Patients with Seasonal Allergic Rhinitis. 21 patients enrolled. Spring 1990.
- 2) A Double-Blind Study for the Safety and Efficacy of a Nasal Steroid Spray in Adults with Mountain Cedar Allergic Rhinitis. 51 patients enrolled. Cedar 1992-1993.
- 3) Double-Blind Comparison Study with a New Oral Asthma Medication in Moderate Asthmatics. 15 patients enrolled. Fall 1993.
- 4) Nasal Spray Comparison Study for Patients with Allergic Rhinitis in Fall. 24 patients enrolled. Fall 1993.
- 5) A Comparison Nasal Spray Study for Patients with Seasonal Allergic Rhinitis. 32 patients enrolled. Fall 1994.
- 6) Comparison Study of a Nasal Spray in the Treatment of Mountain Cedar Allergic Rhinitis in Adult Patients. 38 patients enrolled. Cedar 1994-1995.
- 7) A Comparison Study of Two Marketed Nasal Steroids in the Treatment of Patients with Seasonal Allergic Rhinitis. 43 patients enrolled. Fall 1996.
- 8) Patient Preference and Sensory Comparisons of Three Different Marketed Aqueous Nasal Sprays in Patients with Seasonal Allergic Rhinitis. 30 patients enrolled. Fall 1997.
- 9) A Multi-Center, Double-Blind, Placebo-Controlled, Randomized Comparative Study to Compare the Efficacy and Safety of a New Antihistamine, a marketed antihistamine and Placebo all Given Once Daily for Four Weeks in the Treatment of Seasonal Allergic Rhinitis. 48 patients enrolled. Fall 1997.
- 10) A Multi-Center, Double-Blind, Placebo-Controlled, Parallel, Randomized Study to Compare the Efficacy and Safety of an Allergy Medication Given Once a Day With and Without Food for 2 Weeks in the Treatment of Seasonal Allergic Rhinitis. 100 patients enrolled. Cedar 1998-1999.
- 11) A Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Randomized Comparative Study to Compare the Efficacy and Safety of Two Different Doses of a New Antihistamine vs Loratadine 10 mg and Placebo All Given Once Daily for Four Weeks in the Treatment of Seasonal Allergic Rhinitis. 56 patients enrolled. Fall 1999.

R.W. JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE

- 1) Efficacy, Safety and Comparison Study of a New Antihistamine for Patients with Ragweed Rhinitis. 32 patients enrolled. Fall 1990.

SANKYO

- 1) Randomized, Placebo-Controlled, Parallel-Group Study of a New Hypertensive Medication with Long Term Safety Evaluation in Patients with Essential Hypertension. 12 patients enrolled. Fall 1997.
- 2) A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of an Investigational Anti-Hypertensive Medication and Amlodipine Using ABPM in Patients with Essential Hypertension. 12 patients enrolled. 1999-2000.
- 3) A Randomized, Double-Blind, Placebo-Controlled Factorial Study Evaluating the Efficacy and Safety of Co-Administration of an angiotensin receptor blocker plus a calcium channel blocker Compared to Monotherapy in Patients with Mild to Severe Hypertension. 13 patients enrolled. 2005.

SANOFI-AVENTIS

- 1) A multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of a steroid metered-dose inhaler administered either in a once-daily in the morning regimen for 16 weeks or in a qd AM regimen for 12 weeks preceded by a twice-daily regimen for 4 weeks, or in a bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids. 5 patients enrolled. 2005.

SCHERING-PLOUGH

- 1) A Double-Blind Comparison Study of Inhaled Steroids in the Treatment of Asthma. 32 patients enrolled. 1992-1993.
- 2) A Double-Blind, Safety and Efficacy Study of Nasal Steroids for Treatment of Seasonal Allergic Rhinitis. 45 patients enrolled. Fall 1992.
- 3) Dose-Ranging Study for the Safety and Efficacy of a Steroid Nasal Spray in Patients with Seasonal Allergic Rhinitis. 34 patients enrolled. Fall 1992.
- 4) A Study of the Efficacy and Safety of a New Antibiotic in the Treatment of Acute Maxillary Sinusitis. 4 patients enrolled. Summer 1993.
- 5) Nasal Spray Comparison Study for Patients with Allergic Rhinitis in Fall. 36 patients enrolled. Fall 1993.
- 6) Double-Blind Comparison Nasal Spray Study for Patients with Perennial Allergic Rhinitis. 24 patients enrolled. Fall/Winter 1993-1994.

- 7) Long-Term Open-Label Study of a Nasal Steroid in Patients with Perennial Allergic Rhinitis. 17 patients enrolled. Cedar 1993-1994.
- 8) Antihistamine/Decongestant Component vs Placebo for Patients with Seasonal Allergic Rhinitis. 32 patients enrolled. Fall 1994.
- 9) A Double-Blind, Dose-Ranging Study of the Safety and Efficacy of a Nasal Steroid in the Treatment of Children (Ages 6-11) with Seasonal Allergic Rhinitis. 38 patients enrolled. Spring 1996.
- 10) A Double-Blind, Safety Study Comparing Two Nasal Steroids to Treat Children with Perennial Allergic Rhinitis. 14 patients enrolled. 1996-1997.
- 11) Placebo-Controlled, Efficacy and Safety Study of an Inhaled Dry Powder Steroid in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Beta-Agonists. 16 patients enrolled. 1997.
- 12) A Double-Blind Study to Evaluate an Antihistamine and Decongestant Alone and in Combination in Patients with Seasonal Allergic Rhinitis. 39 patients enrolled. Spring 1997.
- 13) Placebo-Controlled, Dose-Ranging Study of a New Corticosteroid Metered Dose Inhaler Compared to a marketed steroid inhaler in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids. 17 patients enrolled. 1997-1998.
- 14) Efficacy and Safety of Two Dose Levels of an Intranasal Corticosteroid or Placebo in the Treatment of Acute Episodes of Sinusitis. 18 patients enrolled. 1997-1998
- 15) A Long-Term Safety Study of a Nasal Corticosteroid Inhaler in Patients with Perennial Allergic Rhinitis. 24 patients enrolled. 1998.
- 16) Placebo-Controlled Efficacy and Safety Study of a Once Daily, PM Regimen, of a Dry Powder Inhaled Steroid in Asthmatics Previously Maintained on Short-Acting Inhaled Beta-Agonists. 12 patients enrolled. 1999.
- 17) Dose-Ranging Study of an Aerosol Nasal Corticosteroid in the Treatment of Patients with Seasonal Allergic Rhinitis. 28 patients enrolled. Spring 1999.
- 18) Efficacy and Safety of an Antihistamine in the Treatment of Chronic Idiopathic Urticaria. 10 patients enrolled. Summer 1999.
- 19) Efficacy and Safety of an Antihistamine in the Treatment of Patients with Seasonal Allergic Rhinitis. 60 patients enrolled. Fall 1999.
- 20) A Double-Blind, Placebo-Controlled Study with an Antihistamine in the Treatment of Subjects 12 Years of Age with Perennial Allergic Rhinitis. 21 patients enrolled. 1999.

- 21) Efficacy and Safety of an Investigational Antihistamine and a marketed antihistamine in the Treatment of Subjects with Seasonal Allergic Rhinitis. 33 patients enrolled. Fall 1999.
- 22) Efficacy and Safety of an Investigational Antihistamine QD in Subjects with Seasonal Allergic Rhinitis. 42 patients enrolled. Fall 1999.
- 23) Efficacy and Safety of a Leukotriene Inhibitor/Antihistamine Combination in Subjects with Seasonal Allergic Rhinitis and Concurrent Asthma. 12 patients enrolled. 1999-2000.
- 24) A Study of the Effect of an Antihistamine/Decongestant Combination on Nasal Stuffiness in Subjects with Seasonal Allergic Rhinitis. 40 patients enrolled. Spring 2000.
- 25) Efficacy and Safety of 3 Doses an Antihistamine/Decongestant Combination in the Treatment of Subjects with Seasonal Allergic Rhinitis. 32 patients enrolled. Fall 2000.
- 26) Efficacy and Safety of Combination leukotriene receptor antagonist/antihistamine QD vs. its Components in the Treatment of Subjects with Seasonal Allergic Rhinitis. 29 patients enrolled. Fall 2000.
- 27) Placebo-Controlled Efficacy and Safety Study of a Once-Daily PM and Twice Daily Regimens of an Inhaled Corticosteroid Administered Via Dry Powder Inhaler in Subjects with Asthma who were Previously Maintained on Inhaled Steroids. 12 patients enrolled. 2001.
- 28) Efficacy and Safety of Combination antihistamine/ leukotriene receptor antagonist QD vs antihistamine and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis and a History of Perennial Allergic Rhinitis. 10 patients enrolled. Spring 2001.
- 29) Efficacy and Safety of Combination QD vs. antihistamine and Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis. 16 patients enrolled. Spring 2001.
- 30) A Pilot Study of the Effect of an Antihistamine on Nasal Congestion in a Subset of Subjects With Seasonal Allergic Rhinitis. Spring 2001.
- 31) Efficacy and Safety of Combination QD antihistamine/Leukotriene receptor antagonist vs. antihistamine and Placebo in the Treatment of Subjects with Seasonal Allergic Rhinitis and a History of Perennial Allergic Rhinitis. 10 patients enrolled. 2001.
- 32) A Placebo-and Active-Controlled Efficacy and Safety Study of a Once-Daily Fixed Combination Tablet of antihistamine 5mg / decongestant 120mg in Subjects with Seasonal Allergic Rhinitis. 33 patients enrolled. 2002.
- 33) Comparison of Sedation and Performance Impairment Measures in Untreated Healthy Atopic Symptomatic Subjects Receiving Two Marketed Antihistamines or Placebo. 16 patients enrolled. 2003.

- 34) Pilot Efficacy and Safety Field Trial of a marketed antihistamine administered Concomitantly with a marketed anticholinergic, in Subjects With Seasonal Allergic Rhinitis and Post-Nasal Drip. 17 patients enrolled. 2005.
- 35) A Placebo-Controlled Study of the Effects of an antiviral Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure. 7 patients enrolled. 2006.
- 36) Efficacy and Safety of a Combination of an Antihistamine and Leukotriene Inhibitor QD vs. a Decongestant and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis. 30 patients enrolled. 2006.
- 37) A 26-Week Placebo-Controlled Efficacy and Safety Study of Inhaled Seroid/Long-Acting Bronchodilator Combination Formulation Compared With Inhaled Steroid and Long-Acting Bronchidilator Monotherapy in Subjects with Persistent Asthma Previously Treated With Low-Doses Inhaled Glucocorticosteroids. 2 patients enrolled. 2007.
- 38) 26-Week Placebo-Controlled Efficacy and Safety Study of Inhaled Seroid/Long-Acting Bronchodilator Combination Formulation Compared With Inhaled Steroid and Long-Acting Bronchidilator Monotherapy in Subjects with Persistent Asthma Previously Treated With Medium-Dose Inhaled Glucocorticosteroids. 0 patients enrolled. 2007.
- 39) Efficacy and Safety of a steroid Nasal Spray (MFNS) vs Placebo as Adjunctive Treatment to Antibiotics in Relief of Symptoms of Acute Bacterial Sinusitis. 4 patients enrolled. 2007.
- 40) Placebo-Controlled Study of a Steroid Nasal Spray in the Treatment of Seasonal Allergic Rhinitis. 20 patients enrolled. 2007.
- 41) An Open-Label, Multi-Center, Patient Handling Study of a Corticosteroid/Long-Acting Beta Agonist MDI with an Integrated Dose Counter in Adolescent and Adult Subjects with Asthma or COPD. 8 Patients Enrolled. 2008.
- 42) Placebo-Controlled Study of an Intranasal Corticosteroid in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR). 15 Patients Enrolled. Fall 2008.

SEPRACOR

- 1) The Evaluation of 3 Doses of an Investigational Antihistamine and a Marketed Antihistamine when Administered to Subjects with Seasonal Allergic Rhinitis. 60 patients enrolled. Fall 1998.
- 2) A Twelve-Month Safety Study of an Antihistamine Taken Once a Day in Subjects with Perennial Allergic Rhinitis / Seasonal Allergic Rhinitis. 30 patients enrolled. 1999-2000.
- 3) The Evaluation of an Investigational Antihistamine vs a marketed antihistamine vs Placebo when Administered to Subjects with Seasonal Allergic Rhinitis. 24 patients enrolled. Fall 1999.

- 4) The Evaluation of an Investigational Antihistamine and Placebo when Administered to Subjects with Seasonal Allergic Rhinitis Using an Outdoor Allergen Challenge Model. 141 patients enrolled. Cedar 2000.
- 5) The Evaluation of an Antihistamine Administered to Subjects with Seasonal Allergic Rhinitis During the Mountain Cedar Pollen Season. 108 patients enrolled. Cedar 2001.
- 6) A Double-Blind, Placebo and Active Controlled Parallel Group Study of antihistamine Administered to Subjects with Seasonal Allergic Rhinitis. 45 patients enrolled. 2002.
- 7) A Double-Blind, Double-Dummy, Randomized, Placebo-and Active-Controlled, Multicenter, Parallel-Group Study of a long-acting beta-agonist in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease. 25 patients enrolled. 2002-2003.
- 8) A Long Term Safety Study of Two Short-Acting Bronchodilators in Subjects Twelve Years of Age and Older with Asthma. 8 patients enrolled. 2004.
- 9) A Study to Determine the Reliability of a Top Mount Actuation Indicator When Used with a Short-Acting Bronchodilator MDI in Adult and Pediatric Subjects with Asthma or Chronic Obstructive Pulmonary Disease. 8 patients enrolled. 2005.
- 10) A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Clinical Trial to Assess the Efficacy and Safety of an Intranasal Corticosteroid HFA Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older. 96 Patients Enrolled. Cedar 2008-2009.

SHIONOGI

- 1) A Double Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of a Central Nervous System-Mediated Weight-Control Drug Administered Orally Once Daily with an Initial 6-Week Low Calorie Diet in Obese Males and Females. 30 patients enrolled. 2007.
- 2) Open-Label Extension (OLE) Safety and Efficacy Study of a Central Nervous System-Mediated Weight-Control Drug Administered Orally Once Daily Following the Year-Long Controlled Clinical Trials of the Central Nervous System-Mediated Weight-Control Drug in Obese Males and Females. 16 Patients Enrolled. 2008.

SKYE PHARMA

- 1) A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multicenter, 12-Week Study Comparing the Safety and Efficacy of an Inhaled Steroid and Long-Acting Bronchodilator Combination in a Single Inhaler with the Administration of an Inhaled Steroid and a Long-Acting Bronchodilator Alone in Adolescent and Adult Patients with Mild to Moderate Asthma. 7 patients enrolled. 2006.

SMITH KLINE LABORATORIES

- 1) Anti-Hypertensive Dose Ranging Study of a Diuretic. 40 patients enrolled. 6/1986.

- 2) Comparison Study of a New Antihypertensive Medication in Patients with Mild to Moderate Hypertension. 13 patients enrolled. 1/1988.
- 3) A Double-Blind, Dose-Ranging Study of an Allergy Medication for Safety and Efficacy in Patients with Seasonal Allergic Rhinitis. 32 patients enrolled. Spring 1995.
- 4) A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of an Oral BID Dosing of an Asthma Medication in Pediatric Patients with Mild to Moderate Asthma. 10 patients enrolled. 1995.

SUN PHARMACEUTICALS

- 1) Efficacy and Safety of an oral antihistamine in Subjects with Symptoms of Seasonal Allergic Rhinitis: A Randomized, Double Blind, Placebo Controlled, Comparative, Multicenter, Parallel Groups Study. 32 patients enrolled. 2006 and 2007.

SYNTA

- 1) A Phase 2 Study of an anti-psoriasis therapy as Monotherapy in Patients with Chronic Moderate-to-Severe Plaque Psoriasis. 11 patients enrolled. 2004.

TAP

- 1) A Study to Compare the Safety and Efficacy of a Proton Pump Inhibitor Plus Usual Asthma Care vs Placebo Plus Usual Asthma Care in Relieving Asthma Symptoms of Subjects with Asthma and Suspected Gastroesophageal Reflux (GER). 2000.

TEIJIN

- 1) A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Assess the Safety and Efficacy of TBN-15 in Adult Patients with Seasonal Allergic Rhinitis. 121 patients enrolled. 2002-2003.

TEVA

- 1) A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of a steroid Nasal Spray with another steroid Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis. 64 patients enrolled. 2004.

3 M PHARMACEUTICALS

- 1) A 12-Week Safety and Efficacy Study of a New Inhaled Formulation in Patients with Reversible Obstructive Airway Disease. 22 patients enrolled. Fall 1993.
- 2) Twelve Month, Open-Label Safety and Efficacy Study Using a Bronchodilator in a New Device for the Treatment of Reversible Obstructive Airway Disease. 38 patients enrolled. September 1994.
- 3) Six Week Comparison Study for Subjects with Mild to Moderate Reversible Obstructive Airway Disease. 20 patients enrolled. Summer/Fall 1995.

- 4) A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Evaluation of an Anti-Ulcer Drug for the Reduction of Severity or Prevention of Meal-Induced Heartburn. 11 patients enrolled. December 1996.
- 5) Exercise Challenge Dose Response Study of an Inhaled Steroid in Patients with Reversible Obstructive Airway Disease. 13 patients enrolled. 1997.
- 6) Dose Response Comparison of an Inhaled Steroid with New Propellant Inhalation Device with Inhaled Steroid with New Propellant in Press & Breathe MDI in Patients with Asthma. 12 patients enrolled. 1998.
- 7) Safety and Efficacy Study of HFA-134a Albuterol Sulfate Delivered from a Press-and-Breathe MDI, HFA-134a Albuterol Sulfate Delivered from the Autohaler™ Inhalation Device, and HFA-Placebo in Patients with Asthma. 12 patients enrolled. 1999.
- 8) A 12-Week Comparison of Daily Doses of 100 mcg and 200 mcg of Inhaled Steroid with New Propellant in the Autohaler™ Device Versus Placebo in Pediatric Patients with Symptomatic Asthma. 7 patients enrolled. 1999-2000.

UCB PHARMA

- 1) A Double-Blind, Randomized, Placebo Controlled, Multicenter, Phase II Study with Five Parallel Groups, Comparing the Efficacy and Safety of Oral Antihistamine Tablets Administered Twice a Day and Oral Antihistamine Tablets Administered Once a Day in the Morning for Two Weeks Versus Placebo in Subjects Suffering from Seasonal Allergic Rhinitis. 51 patients enrolled. 2002.
- 2) A Multi-center, Randomized, Double Blind, Placebo Controlled Parallel Group Study of the Safety of a Non-sedating Antihistamine Oral Liquid Formulation b.i.d. dosing in Children Aged 2 to 6 Years Suffering from Allergic Rhinitis or Chronic Urticaria of Unknown Origin. 25 Patients Enrolled. 2008.
- 3) A multi-center, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and impact on health-related quality of life of Non-sedative Antihistamine 5 mg once daily given for 2 weeks in subjects 18 yr of age and older with seasonal allergic rhinitis. 38 Patients Enrolled. 2008.

UPJOHN

- 1) Comparison of Oral Antibiotic in the Treatment of Acute Maxillary Sinusitis in Adults. 25 patients enrolled. 1995-96.
- 2) Open-Label Study to Evaluate the Use of a Cholesterol Medication in the Treatment of Hypercholesterolemia. 200 patients enrolled. 1997.

VICKS

- 1) An NSAID Dosing Compliance Study. 100 patients enrolled. 1989.

VIRO PHARMA

- 1) A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Clinical Efficacy, Virologic Activity, And Safety Of an antiviral medication (Oral Suspension) In The Treatment Of Viral Respiratory Infection In Children 1 To 6 Years Of Age. 2001.
- 2) A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Clinical Efficacy, Virologic Activity, And Safety Of Pleconaril (Oral Suspension) In The Treatment Of Viral Respiratory Infection In Children 7 To 12 Years Of Age. 2001.

WALLACE

- 1) Comparison of the Effectiveness and Safety of a New Asthma Medication in the Management of Symptomatic Bronchial Asthma. 30 patients enrolled. Spring 1988.
- 2) Safety, Efficacy and Duration of Action Study of a New Asthma Medication for Patients with Chronic Asthma. 14 patients enrolled. 1988.
- 3) Safety and Efficacy Study of a New Nasal Spray in Seasonal Allergic Rhinitis. 50 patients enrolled. Winter 1990.
- 4) Comparative Study to Assess the Safety and Efficacy of a New Medication in the Management of Seasonal Allergic Rhinitis. 50 patients enrolled. Spring 1991.
- 5) A Randomized, Double-Blind, Placebo-Controlled Trial of antihistamine nasal spray, antihistamine in Patients With Seasonal Allergic Rhinitis. 31 patients enrolled. 2002.

WARNER LAMBERT

- 1) Comparison of the Efficacy of Two Marketed Oral Antihistamines in Seasonal Allergic Rhinitis. 80 patients enrolled. Cedar 1995.

WEST

- 1) A Multi-center, Three-arm, Parallel-group, Double-blind, Randomized Study of the Efficacy and Safety of an Intranasal Corticosteroid Compared to a Marketed Corticosteroid and Placebo in Subjects with Seasonal Allergic Rhinitis During the Fall Allergy Season. 40 patients enrolled. 2003.

WHITEHALL LABORATORIES

- 1) A Double-Blind Comparison Study of 2 Doses of one antihistamine vs another antihistamines in Patients with Allergic Rhinitis. 40 patients enrolled. Fall 1992.

WHITEHALL-ROBINS

- 1) NSAID Multi-Symptom Allergy Sinus Efficacy and Safety Study. 22 patients enrolled. Spring 2001.
- 2) A Pilot Study of the Effect of an Antihistamine on Nasal Congestion in a Subset of Subjects with Seasonal Allergic Rhinitis. Spring 2001.

ZENECA

- 1) Double-Blind Comparison Study of a New Asthma Medication in Mild to Moderate Asthmatic Patients. 9 patients enrolled. 1993-1994.

- 2) Double-Blind Study to Compare Efficacy of a New Oral Asthma Medication Over 13 Weeks in Patients with Mild to Moderate Asthma. 14 patients enrolled. 1993-1994.
- 3) One Year Open-Label Study of a New Oral Medication for Treatment of Patients with Mild to Moderate Asthma. 2 patients enrolled. May 1994.
- 4) A Double-Blind, Placebo-Controlled Trial of an Oral Medication for Mild to Moderate Asthmatics. 13 patients enrolled. 1995-1996.
- 5) A Double-Blind, Dose-Ranging Study of the Safety and Efficacy of a Leukotriene Receptor Antagonist and an Antihistamine in Patients with Seasonal Allergic Rhinitis. 64 patients enrolled. 1996.
- 6) A 13-week Double-Blind Study Comparing Two Doses of Medication Given in Combination with an Inhaled Corticosteroid vs High-Dose Corticosteroid Alone in Patients with Mild to Moderate Asthma. 13 patients enrolled. 1996.
- 7) A Dose-Ranging, Safety, and Efficacy Trial with an Oral Medication in the Treatment of Pediatric Subjects with Mild to Moderate Asthma. 17 patients enrolled. 1997.
- 8) A Multi-Center, Randomized, Double-Blind, Dose Escalation Trial to Compare the Effect of Oral Doses of an Asthma Medication in Subjects with Mild to Moderate Asthma. 30 patients enrolled. 1997.
- 9) An Open-label, Multi-Center Trial Providing Progressive Options, Widening Experience and Relief with a New Marketed Medication in the Acute treatment of Migraine Headaches. 3 patients enrolled. 1998.
- 10) A Multi-Center, Double-Blind Comparison of an Asthma Medication with Placebo in Pediatric Subjects with Mild-to-Moderate Asthma. 10 patients enrolled. 1998-1999.